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There currently is an unmet need for new diagnostics to monitor Alzheimer’s 
disease (AD) and a lack of understanding of the metabolic processes, in particular 
leucine deprivation on disease and the autophagy pathway. It is thought that there 
is an altered metabolic profile related to AD that could be used to monitor the 
progression of patients and offer possible targets for treatment. 
Findings:  
The results presented show for the first time that measurement of BCATm and 
the amino acids increased the sensitivity and specificity of MoCA analysis in 
correctly identifying participants free of AD pathology (100%) but also those with 
the disease to 90% accuracy, with BCATm and Glutamate, significantly improve 
the predictive potential of MoCA, and significantly improve the predictive potential 
of the MRI measures. 
 
Additionally, this research has shown that leucine and nutrient deprivation causes 
a significant decrease in intracellular glutamic acid and causes increased 
expression of markers of autophagy Beclin 1 and LC3. Metabolic analysis has 
additionally shown that in cases of acute leucine deprivation cellular metabolism 
is significantly altered. 
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Chapter 1 – Introduction 
 
1.1.1 – Dementia  
Dementia is defined as a chronic and progressive clinical syndrome characterised 
by cognitive decline resulting in interference with social or occupational 
functioning (Chertkow et al., 2013). Syndromes include; frontotemporal dementia, 
Lewy body dementia, vascular dementia and Alzheimer’s disease (AD). Dementia 
as a whole has associated social and economic costs with The World Health 
Organisation (WHO) estimating a spend of US$818 billion on Dementia care in 
2015 (W.H.O, 2019). Current therapies fall short in significantly delaying or 
controlling the progressive nature of these conditions highlighting the unmet 
clinical need for new approaches to better understand disease pathology (W.H.O, 
2019). Despite recent advances in imaging technology and cognitive 
assessments there are still significant challenges to better characterize disease 
onset. The impact of poor diagnostic and prognostic clinical tools will further delay 
the monitoring of effective treatment, highlighting the need for targeted research 
in these areas.  
 
The pathological outcome of neurodegenerative disease is dependent on the area 
of the brain affected and in certain cases defined by the accumulation of specific 
proteins, in addition to alterations in fundamental processes associated with 
neuronal dysfunction and death (Dugger and Dickson, 2017). In Parkinson’s 
disease for example, abnormal deposits of α-synuclein result in the selective 
death of dopaminergic neurons in the substantia nigra causing the impairment of 
motor function (Naoi and Maruyama, 1999). Additionally, deposits in neurons 
have been attributed to result in cognitive impairment and visual hallucinations as 
observed in Lewy body dementia (Duong et al., 2017). This form of dementia 
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accounts for 5-15%  of reported dementia cases (Canada, 2019) and can present 
with spontaneous parkinsonism (Zupancic et al., 2011). Frontotemporal dementia 
encompasses disorders affecting the frontal and temporal brain lobes, where 
neuronal loss causes personality and behavioral changes and unlike other 
neurodegenerative conditions, pathological expression does not include protein 
deposits. Furthermore, this form of dementia can occur at a younger age 
compared to other forms (Duong et al., 2017). Finally, cholinergic neuron loss 
through the deposition of neuritic plaques and neurofibrillary tangles in the 
hippocampus and cerebral neocortex gives rise to the typical clinical 
presentations of AD (Niikura et al., 2006), with reduced synthesis of 
neurotransmitters including acetylcholine, causing loss of memory and function 
(Duong et al., 2017). Abnormalities in autophagy, oxidative stress and 
neuroinflammation are also attributed to many neurodegenerative diseases, 
which are thought to contribute to disease pathology. However, the associated 
pathways present a variety of diagnostic or treatable targets.  
 
1.1.2 - Cognitive Impairment and Neurodegenerative Disease 
It is expected that a level of cognitive decline occurs with normal aging that is not 
classified as dementia. A key criteria for diagnosis of Mild Cognitive Impairment 
(MCI) is the absence of classical dementia (Albert et al., 2011) whereby MCI is 
considered the transitional stage between normal age and education-related 
cognition and mild dementia (Petersen, 2007). Changes in age-related cognition 
with regard to assessment are divided into “crystallised” and “fluid” abilities. 
Crystallised abilities are defined as cumulative skills and memories from 
previously acquired knowledge (Murman, 2015). Fluid abilities are defined during 
cognitive assessment and are determined by participants problem solving ability 
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and their assessment and processing of new information (Murman, 2015). 
Educational related cognition is associated to educational attainment with higher 
education linked to greater cognitive performance under examination (Wilson et 
al., 2009). Furthermore, educational attainment has been linked to reduced risk 
of AD and dementia (Stern et al., 1994, Stern, 2009, Bennett et al., 2003). 
However, there are issues with respect to the relationship of education-related 
cognition and cognitive decline. Firstly, studies have highlighted analytical 
differences caused by biased effect estimates through the use of regression-
based approaches in early studies (Zahodne et al., 2015) and this is shown to 
have a strong relation to variables that are associated with cognitive baseline such 
as years of education (Glymour et al., 2005). Furthermore, in contrast to the 
reported reduction in cognitive decline for higher educated individuals, studies 
have shown that no additional years of education from the median of 11 years 
were associated with slower cognitive decline (Christensen et al., 2004). 
Moreover, there is not an associated reduction in cognitive decline beyond nine 
years of education (Lyketsos et al., 1999). Finally, there are considerations that 
educational attainment results in advantageous cognitive and non-cognitive 
experiences including intellectually demanding activities and significant use of 
intellectual resources through problem solving and complex decision making that 
can affect assessment results (Zahodne et al., 2015, Parisi et al., 2012). These 
inherent issues with analytical methods and the additional considerations for 
educational cognitive assessment highlights the requirement for an alternative 
diagnostic measure for cognitive assessment and prognostic assessment of 
cognitive decline including MCI.  
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Initially MCI was used to describe age-related progressive cognitive decline, 
defined as cognitive impairment of a single domain (Petersen et al., 1999) 
whereby the domains that could be affected include memory, language, attention, 
visuospatial abilities and executive functioning. However, this criteria was revised 
to account for the preservation of functional activity (Petersen, 2004). MCI affects 
19% of people age 65 and over (Lopez et al., 2007), approximately 46% of those 
with MCI will develop dementia within three years compared with the reported 3% 
of age-matched controls (Tschanz et al., 2006). This significant increase in 
disease conversion highlights the importance of developing tools to accurately 
predict and monitor conversion to aid clinicians with prognostic assessment and 
early treatment programs.  
 
Several clinical subtypes of MCI are known, with the most recognised and 
researched form being amnestic MCI. Diagnostic criteria for this form include; 
objective memory impairment for age, referring to a subjective awareness of initial 
memory decline, which cannot be detected using current standardised cognitive 
assessment (Alegret et al., 2015), preserved general cognitive function, largely 
intact functional domain activities including problem solving, reasoning or the 
ability to understand others and no presentation of dementia (Petersen, 2004). 
The presentation of impairment in multiple cognitive domains, including or not 
including memory impairment, is classified as multiple domain-MCI (Petersen, 
2004). Normally affected domains in this subtype can include language, executive 
function and visuospatial skills (Petersen, 2004). The least common form of MCI 
is single non-memory domain MCI, where the domain type that is impaired in this 
form is the same as md-MCI.  
  
Fred Hudd | 2020 
 5 
Of those diagnosed with MCI, a specific subset, which includes those with 
amnestic MCI, has an increased likelihood of progression to AD (Cooper et al., 
2015). However, those that present may not progress to develop AD or dementia. 
Currently, treatment methods or prognostic outcomes for MCI are limited with 
neither UK nor the US health services recommending drug treatments (Cooper et 
al., 2015). Recent investigations have found no consistent evidence of any 
intervention reducing the risk of dementia or cognitive decline associated with 
MCI (Cooper et al., 2013, Cooper et al., 2015). The lack of evidence in treatment 
efficacy and prognostic assessment indicates a significant need for the 
development of new and novel treatments and diagnostic/prognostic tools. Similar 
issues with diagnosis and treatment are seen with other neurodegenerative 
diseases, including Parkinson’s disease and frontotemporal dementia.  
 
1.1.3 - Diagnosis of AD 
Definitive diagnosis of AD requires post-mortem examination of brain tissue to 
identify amyloid plaques and neurofibrillary tangles. The original criteria was 
established and defined by National Institute of Neurological and Communicative 
Disorders and Stroke - AD and Related Disorders Association for the clinical 
assessment of patients (McKhann et al., 1984). Assessment of the disease 
involves categorisation of patients as having possible or probable AD. Probable 
AD presents with typical onset of dementia with progression and no other 
systemic or brain disease present that could cause progressive memory and 
cognitive deficit (McKhann et al., 1984). Possible diagnosis is applied in cases 
where the presentation or disease course is considered aberrant. These criteria 
are based on a variety of clinical examinations including the use of a battery of 
cognitive tests, with the most common test applied being the Mini-Mental State 
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Examination (Folstein et al., 1975). In addition to clinical examination other 
considerations are considered relating to; the number of cognitive areas affected, 
the progressive worsening of cognitive function including aphasia, apraxia and 
agnosia and the lack of disturbance in consciousness (McKhann et al., 1984). 
Recently the introduction of a variety of imaging techniques have been included 
in the clinical assessment of patients with possible AD.  
 
Imaging analysis has had a range of roles in the study and diagnosis of AD with 
its clinical introduction looking to reduce the uncertainty of clinical diagnosis and 
offer a further non-invasive form of examination. Computed tomography and 
magnetic resonance imaging (MRI) have been used in an exclusionary manner 
to rule out possible other causes of dementia or brain injury (Johnson et al., 2012).  
However, developments and additional technology have now allowed imaging to 
be implemented as a diagnostic measure through the identification of 
characteristic signatures for both structural and functional cerebral alterations. 
Additionally, specific assessment of amyloid deposits can be achieved with 
amyloid imaging (Johnson et al., 2012).  
 
Two forms of MRI imaging are now currently utilised, the first, structural MRI, 
allows for the assessment of brain atrophy or changes in tissue characteristics. 
Cerebral atrophy is thought to arise from dendritic and neuronal losses resulting 
in declining cognitive function, with MRI brain volume analysis shown to be closely 
related to neuronal counts (Bobinski et al., 2000, Jack et al., 2002, Gosche et al., 
2002). MRI has additional utility in the assessment of the functional integrity of 
brain networks and an indirect measure of neuronal activity. The measurement of 
blood oxygen levels changes while patients perform cognitive activities involving 
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the processing of new information (Ogawa et al., 1990, Kwong et al., 1992). These 
are considered to reflect neuron synaptic activity with decreased hippocampal 
activity shown in AD patients (Rombouts et al., 2000). These findings together 
highlight MRI assessment as a potential utility for the diagnosis of Alzheimer’s, 
however, currently their main adoption has been investigator-initiated-add-on-
studies.  
 
Positron emission tomography (PET) has also been utilised to study cerebral 
metabolism with fluoro-deoxy-d-glucose (FDG) and conduct amyloid imaging 
studies through the use of amyloid tracers. Studies have shown that these 
techniques can identify characteristic changes associated with AD. The brain’s 
reliance on glucose for an energy source has allowed for the assessment of 
synaptic activity using FDG-PET whereby FDG, a glucose analogue, is labelled 
with Fluorine-18 and monitored by PET (Johnson et al., 2012). Brain uptake of 
FDG has been shown to strongly correlate with autopsy levels of synaptic vesicle 
protein synaptophysin (Rocher et al., 2003) and is widely accepted as a biomarker 
for total brain metabolism (Magistretti, 2006). No single alteration in the 
metabolism has been linked to AD and instead this assessment assumes that any 
noted abnormalities present in AD patients are a result of the diseases 
pathogenesis. However, the collection of a large number of data sets using FDG-
PET show a pooled sensitivity of 91% (95% confidence interval, 86%–94%) and 
specificity of 86% (95% confidence interval, 79%–91%) (Shivamurthy et al., 
2015). Furthermore, FDG-PET has been shown to differentiate AD patients from 
control participants with a 99% sensitivity and 98% specificity (Mosconi et al., 
2008). FDG-PET has additionally been found to perform better than other 
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available imaging techniques for the prediction of MCI to dementia conversion 
(Laforce et al., 2010).  
 
Estimation of brain amyloid β (Aβ) has previously been limited to post-mortem 
assessment, however amyloid PET has allowed for the clinical assessment of 
neuritic Aβ plaque density. Initial research into the use of Amyloid PET imaging 
used the Pittsburgh Compound B (PIB) with correlation between PIB retention 
and the levels of Aβ determined by immuno assay or silver staining at autopsy 
(Ikonomovic et al., 2008, Leinonen et al., 2008). Correlation has also been 
reported with low levels of CSF Aβ42 in all publications that investigated the 
association (Fagan et al., 2006, Grimmer et al., 2009, Jagust et al., 2009, 
Tolboom et al., 2009, Weigand et al., 2011). 
 
The advancements in imaging methods has allowed for their inclusion in the 
revised criteria for AD with the acknowledgement of both neuroimaging and 
laboratory biomarkers as supportive criteria (Dubois et al., 2010). However, their 
adoption into a routine clinical setting is limited due to expense, lack of expertise 
and relevant hardware resulting in the search for alternatives in fluid biomarkers. 
 
1.1.4 – Current and Potential Biomarkers and Disease Markers for 
Alzheimer’s Disease. 
In 1992, one of the first biomarker studies showed that Aβ is secreted into the 
cerebral spinal fluid (CSF), heralding the development of quantitative 
immunoassays for CSF Aβ (Seubert et al., 1992). Subsequent methods published 
in 1995 described the use of an ELISA to detect Aβ42 with analysis showing a 
marked decrease in the CSF levels of Aβ42 in AD (Motter et al., 1995). This finding 
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has been subsequently validated in multiple published articles and shown to 
correlate with amyloid positive PET scans of AD patients (Olsson et al., 2016). 
Additional combined analysis of Aβ species, Aβ40 with Aβ42, demonstrated 
improved diagnostic accuracy (Shoji et al., 1998) despite Aβ40 remaining 
unchanged or only mildly changed in AD (Olsson et al., 2016). The ratio of 
Aβ42/Aβ40 has additionally shown better correlation with amyloid PET positivity 
(Janelidze et al., 2016). 
 
Tau proteins have also been analysed in the CSF of AD patients, with initial 
identification of CSF tau obtained through Western blot analysis (Wolozin and 
Davies, 1987)) and the use of Alz-50 monoclonal antibody (Ksiezak-Reding et al., 
1988). Subsequent analysis focused on the levels of total tau and phosphorylated 
tau. Total CSF tau has been proposed as a marker of neurodegeneration intensity 
or the severity of acute neuronal damage with marked increases found in AD 
patients. Furthermore, combined increases in levels of total tau in addition to 
phosphorylated tau have be shown to be predictive of a more rapid clinical 
disease progression (Zetterberg et al., 2013, Wallin et al., 2010, Buchhave et al., 
2012). 
 
Although promising data has been generated around CSF amyloid and tau 
analysis, these techniques are still not implemented solely for the diagnosis of 
AD. Instead combination assessment with routine cognitive tests and current 
imaging technology is used to provide a more complete clinical picture. Together 
with the development of CSF biomarkers there has been a drive to develop blood-
based biomarkers, which are less invasive with potential for a wider clinical utility. 
Blood biomarkers present a range of new challenges regarding their development  
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and validation. Measurement of brain-derived biomarkers requires highly 
sensitive and specific analysis due to restricted free movement of molecules 
between the central nervous system and the blood by the blood brain barrier, 
resulting in relatively low biomarker concentrations being present (Zetterberg and 
Burnham, 2019). Furthermore, specific blood biomarkers with clinical utility in the 
diagnosis and monitoring of AD are expressed in other sites of the body and 
additionally present issues of analyte degradation by plasma proteases 
(Zetterberg and Burnham, 2019).  
 
As previously discussed, CSF levels of Aβ1-42 and the ratio of Aβ1-42/Aβ1-40 have 
some adoption in specific diagnostic profiling for AD, however plasma Aβ1-42 and 
the ratio of plasma Aβ1-42/Aβ1-40 could present an alternate less invasive option to 
measure Aβ. Current methods for the analysis of plasma Aβ have included the 
application of an ultrasensitive single molecule array for Aβ42, which showed that 
the ratio of Aβ1-42/Aβ1-40 and plasma Aβ was reduced in the plasma of amyloid 
PET-positive individuals (Janelidze et al., 2016). These findings follow the trend 
seen in analysis of the CSF ratio of Aβ1-42/Aβ1-40, however, serum analysis did not 
present with as distinct a separation between AD and control groups as CSF 
analysis of the same biomarker profile (Janelidze et al., 2016). This study 
additionally concluded that the decreased Aβ seen in plasma indicates that 
changes in Aβ metabolism occur later in the periphery compared to the brain and 
that in specific cases of increased plasma Aβ levels there is an association with 








Figure 1.1 – Illustrative 11C-PIB PET-MR, Negative 11C-PIB-PET-MR and FDG-PET 
Imaging of Alzhiemer’s disease brain. 
A -  llustrative 11C-PIB PET-MR of Alzheimer’s disease brain showing high tracer retention in 
frontal lobes with tracer signal lower in the parietal lobe and temporal cortex. B - Negative 
11C-PIB-PET-MR from a patient with symptoms of Alzheimer’s disease, showing a distinctive 
pattern of white matter moderate non-specific tracer uptake. C - FDG-PET imaging of 
cognitively normal subject. D - FDG-PET of a patient with suspected early Alzhimer’s disease. 
E - FDG-PET of a patient with advanced Alzheimer’s disease. Distribution shows avid cortical 
FDG uptake on the grey matter, the basal ganglia, and the thalami in the healthy subject. MCI 
patient demonstrates widespread reduction in the parietal, frontotemporal and basal ganglia 
glucose metabolism. The regional cerebral metabolic rate of glucose is severely impaired on 
the patient with advanced Alzheimer’s disease (Rice and Bisdas, 2017). Reprinted from 
European Journal of Radiology, 94, Louise Rice,Sotirios Bisdas, The diagnostic value of FDG 
and amyloid PET in Alzheimer’s disease—A systematic review, 16-24., Copyright (2007), with 
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Subsequent developments in the analysis of serum Aβ have focused on the 
improvement of diagnostic accuracy while still addressing the same analytical 
parameters. Immunoprecipitation mass spectrometry assays give around a 90% 
diagnostic accuracy with similar decreases in plasma Aβ1-42/Aβ1-40 ratio compared 
to CSF (Nakamura et al., 2018, Ovod et al., 2017). Although these assays present 
promising data for Aβ as a plasma biomarker, they do not account for non-
cerebral expression of Aβ as seen in platelets (Li et al., 1994) and therefore are 
subject to scrutiny regarding analysis specificity.  
 
Similar developments have been made in the analysis of plasma tau, with the use 
of Single Molecule Array (Simoa) finding that the levels of total tau in plasma are 
increased in cases of cognitive decline and that these increased levels are 
associated with faster clinical disease progression and have an association with 
the incidence of AD (Mielke et al., 2017, Pase et al., 2019). Furthermore, the 
analysis of plasma phosphorylated tau using a biotinylated-AT270 capture 
antibody for pTau181 presented a more sensitive and specific predictor of 
elevated brain Aβ (Mielke et al., 2018). Furthermore, levels of pTau181 were 
shown to be elevated in AD compared to participants classified as cognitively 
unimpaired (Mielke et al., 2018). This increased profile is supported by analysis 
with both immunomagnetic reduction technology and Simoa (Tatebe et al., 2017).  
 
MicroRNA (miRNA) expression profiling for neurodegenerative disease has also 
gained traction with the Real-Time PCR offering both accurate and inexpensive 
detection of circulating miRNAs in serum and CSF (Weber JA, 2010). miRNAs 
selectively bind messenger RNAs, downregulating their translation into proteins, 
controlling key biological processes including neurogenesis and immune 
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response and having a fundamental role in cellular expression homeostasis 
(Schmiedel JM, 2015). Successful analysis of CSF miRNAs reported differential 
expression of miR-100, miR-146a and miR-1274a in AD (Denk et al., 2015). 
Furthermore, discrimination analysis of these targets was able to positively 
classify controls and AD cases with 95.5% accuracy for AD diagnosis (Denk et 
al., 2015). MiRNA additionally offers a potential avenue for disease monitoring 
with correlations seen with the levels of Aβ1-42 and phosphorylated neurofilament 
heavy chain (Denk et al., 2018). 
 
Efforts have also been made to target multiple affected pathways using 
proteomics or metabolomics platforms to predict AD onset. These studies have 
focused on the generation of metabolic profiles that could be used collectively to 
better differentiate between MCI, AD and early disease stages (Lista et al., 2013). 
The combination of these assays combined with high throughput mass 
spectroscopy analysis offer exciting new opportunities to better diagnose causes 
of cognitive impairment. A key focus of this thesis will aim to investigate the 
potential for the branched chain aminotransferase protein (BCAT) and its 
metabolite, glutamate to predict AD progression relative to control and MCI 
offering a novel biomarker to predict disease onset.  
 
2.1.1 - Alzheimer Disease  
AD is the most common form of dementia, accounting for an estimated 60-70% 
of dementia cases, with an estimated 46.8 million people affected worldwide and 
cases increasing by approximately 4.6 million each year (Irvine et al., 2008, Prince 
et al., 2016). The disease is characterised by initial presentation of cognitive 
dysfunction, including memory loss (determined through clinical assessment or 
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anecdotal evidence) disorientation with speech and language issues. The second 
sub-set of symptoms are deemed non-cognitive and include the presentation of 
psychiatric symptoms which include depression, hallucinations, delusion and in 
certain cases aggressive behaviour. These factors form the overall symptomatic 
presentation of cognitive impairment, and with regard to AD are due to the frontal, 
parietal, and the temporal lobe being affected.  
 
In the majority of cases, the disease is age-related with the highest percentage of 
patients classified as having late onset AD with symptomatic presentation after 
the age of 65. Cases of AD occurring before the age of 60 are considered 
exceptional (Wolk and Dickerson, 2019) and classified as early onset AD (Wolk 
and Dickerson, 2019). Similar early presentation is observed in cases of genetic 
autosomal dominant forms of AD, although genetic risk factors, which play a 
strong role even in the development of late onset AD (Gatz et al., 2006). Specific 
genetic factors have been seen to contribute to AD with fully penetrant mutations 
in Amyloid precursor protein (APP), Presenilin 1, and Presenilin 2 discovered as 
causes of the autosomal dominant form of AD (Van Cauwenberghe et al., 2016) 
(Table 1.1.1).  
 
Furthermore, the presence of the ɛ4 allele of Apolipoprotein E (APOE) has been 
shown to indicate strong genetic risk for both early-onset and late-onset AD 
(Saunders et al., 1993). The APOE coding region encodes a polymorphic 
glycoprotein expressed at multiple sites in the body, including the liver, brain, 
macrophages, and monocytes (Van Cauwenberghe et al., 2016). In the brain 
ApoE has a role in transport of lipids, neuronal growth and tissue response. 
Additionally, multiple studies have shown a relationship between ApoE and the 
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clearance of soluble Aβ and Aβ aggregations (Huynh et al., 2017, Deane et al., 
2008). In the microglia, ApoE has been shown to enhance the degradation of Aβ 
by the zinc-dependent metalloprotease neprilysin that additionally facilitate the 
insulin degrading enzyme degradation of extracellular Aβ (Jiang et al., 2008).  
 
Three main allelic variations; ɛ2, ɛ3, and ɛ4 encode for the ApoE2, ApoE3, and 
ApoE4 isoforms, respectively (Corder et al., 1993). The ɛ4 isoform is thought to 
be less efficient in mediating the clearance of Aβ (Corder et al., 1993) and carries 
an associated three-fold or fifteen-fold increased risk of AD for heterozygous 
APOE ɛ3/4 and ɛ4/4 forms respectively. However, this mutation is not individually 
sufficient to cause the disease (Corder et al., 1993, Saunders et al., 1993, Farrer 
et al., 1997). Conversely, a protective effect and delay of onset age is associated 
with APOE ɛ2 (Corder et al., 1994). 
 
The study of these mutations has allowed for the development of the current 
understanding of key pathological observations of AD. These include the key 
hallmarks of accumulation of extracellular Aβ plaques and intracellular 
accumulation of neurofibrillary tangles containing hyperphosphorylated tau, 
together with neurotransmitter imbalances, which result in neuronal deficit 
(Glenner and Wong, 2012).  
 
2.1.1.1 – The Amyloid Hypothesis 
Under normal physiological conditions Aβ is produced through APP processing 
by astrocytes and neurons in the brain (Puig and Combs, 2013) and is typically 
present as a soluble form which is secreted extracellularly for clearance by the 
CSF. APP can be processed in two different ways by different sets of enzymes – 
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the first is the non-amyloidogenic pathway and the second pathway 
(amyloidogenic) leads to the hallmark amyloid plaque formation in AD. 
 
Usually around 90% of APP enters the non-amyloidogenic pathway, and 10% 
follows the alternative amyloidogenic path, but these ratios can change due to 
mutations, environmental factors, as well as the age of the individual. Through 
the non-amyloidgenic pathway APP is cleaved by α-secretase generating a 
soluble N-terminal fragment and a C-terminal (CTFα) membrane-bound fragment. 
CTFα undergoes further clevage by presenilin-containing γ-secretase to generate 
a soluble N-terminal fragment (p3) and a membrane-bound C-terminal fragment 
(AICD, or APP intracellular domain) (Chow et al., 2010). The products from this 
pathway have been shown to promote memory retention through the regulation 
of neurite outgrowth and synaptogenesis.  
 
Alternatively, APP may also be processed through the ‘plaque forming’ 
amylogenic pathway, generating the more commonly known toxic form of Aβ 
(Murphy and LeVine, 2010). In this pathway, rather than the initial cleavage by α-
secretase, APP is cleaved by β-site APP cleavage enzyme 1 (BACE) (a 
transmembrane aspartic protease), generating a shorter sAPPβ. In this instance 
the remaining membrane-bound C-terminal fragment (CTFβ) is cleaved closer to 
the N-terminal end of APP than with α-secretase, generating a longer fragment 
than CTFα.
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Table 1.1 – Genes associated with Alzheimer’s disease 
Gene  Chromosome Location Normal Function Inheritance AD Pathology  
Amyloid Precursor Protein 21q21 Regulation of synaptic function Autosomal Dominant Early onset 
Apolipoprotein E 19q13.32 Cholesterol transport Sporadic Genetic risk factor  
Presenilin 1 14q24.2 Processing of APP and formation of Aβ Autosomal Dominant Early onset 
Presenilin 2 1q42.13 Processing of APP and formation of Aβ Autosomal Dominant Early onset 
Table Adapted from Genetics of Alzheimer’s disease and Role of glutamate and NMDA receptors in Alzheimer’s disease (Bekris et al., 2010, Wang and Reddy, 
2017). 
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Although this is followed by γ-secretase cleavage forming AICD, the same as 
reported for the non-amyloidgenic pathway, a soluble N-terminal fragment (Aβ) 
that is longer than p3 is also produced. These varying lengths of Aβ include two 
main species, Aβ1–40(90%) and Aβ1–42 (10%) (Van Cauwenberghe et al., 2016). 
The larger Aβ1–42 fragments are those found predominantly in the plaques in AD 
brain and are prone to aggregation due to additional hydrophobic residues 
(Selkoe, 2001, Walsh and Selkoe, 2007). In contrast to the a pathway, APP 
processing through the β-synuclein pathway has been shown to promote memory 
loss and reorganisation through neuronal apoptosis and neurite retraction 
(Bredesen, 2009). Furthermore, the accumulation of Aβ1–42 fragments has been 
shown to result in aggregate-mediated toxicity, increasing oxidative stress 
through the reduction of metal ions (Huang et al., 1999).  
 
Research into the role of Aβ has focused around its role in disease pathology, 
with less emphasis into understanding its normal physiological role. There is 
increasing evidence that there is an important role for soluble Aβ in synaptic 
plasticity and memory (Puzzo and Arancio, 2013, Morley and Farr, 2014, Brothers 
et al., 2018). The release of Aβ into the synaptic cleft has been shown to increase 
the probability of neurotransmitter release from presynaptic neurons following 
synapse transport of APP during neuronal activity and subsequent cleavage 
(Kamenetz et al., 2003, Cirrito et al., 2005, Tampellini et al., 2009). 
 
Moreover and relating directly to the central nervous system, Aβ has shown the 
capability to plug ‘leaks’ in the blood brain barrier (Brothers et al., 2018). The 
blood brain barrier describes the microvasculature of the central nervous system 
which regulates the transport of molecules, ions and cells to and from the blood 
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(Zlokovic, 2008). The highly restrictive nature of the blood brain barrier allows for 
tight regulation of central nervous system homeostasis and protection from any 
blood borne toxins or pathogens, and from inflammation and disease (Daneman 
and Prat, 2015). In neurological disease, neurodegenerative disorders and 
instances of brain trauma barrier properties are altered, causing changes to 
signalling, ion dysregulation and allow for immune cells entry into the central 
nervous system (Daneman and Prat, 2015, Zlokovic, 2008). These imbalances 
and entry of foreign cells can cause both neuronal dysfunction and degeneration 
(Daneman and Prat, 2015). Aβ has also been shown to have a definitive link with 
the integrity of the blood brain barrier, with study of Aβ plaques in AD showing the 
presence of serum albumin and collagen IV which are not found in the brain under 
normal conditions (Cullen et al., 2006). In instances where the blood brain barrier 
becomes ‘leaky’, soluble Aβ has been shown to form an insoluble mass by binding 
pro-inflammatory and neuroactive compounds and stopping any further spread 
throughout the brain (Bishop and Robinson, 2002). Therefore, understanding the 
normal physiological role of Aβ will be important before further therapeutic 
targeting is developed. 
 
2.1.1.2 – Microtubule-Associated Protein Tau Hypothesis  
The second key pathological hallmark of AD is the accumulation of intracellular 
neurofibrillary tangles, which arise from abnormal hyperphosphorylation of the 
mature neuron microtubule protein tau (Goedert and Crowther, 1989, Goedert et 
al., 1989). Tau promotes the assembly and stabilisation of microtubules through 
its interactions with tubulin (Weingarten et al., 1975) with its biological function 
regulated through phosphorylation and alternative mRNA splicing (Stoothoff and 
Johnson, 2005). Through the investigation of the abnormal hyperphosphorylation 
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of tau studies have identified the specific phosphatases and kinases responsible 
for this process. Glycogen-synthase kinase-3β (GSK-3β), has been shown to 
have a role in both the regulation of tau splicing through the phosphorylation of 
the nuclear splicing element enhancer SC35 (Hernandez et al., 2004) and tau 
phosphorylation. Phosphorylation of GSK-3β at Ser9 is recognised by the 
scaffolding protein 14-3-3 which forms a complex with tau in the brain (Agarwal-
Mawal et al., 2003). When this complex is present, GSK-3β is active leading to 
tau phosphorylation (Agarwal-Mawal et al., 2003). The phosphorylation of tau at 
Thr231 and Ser400 by GSK-3β has been shown to be promoted by priming of the 
tau residues Ser235 and Ser404 by cyclin-dependent protein kinase 5 (cdk5) 
(Cho and Johnson, 2003). Tau phosphorylation is further modulated by cAMP-
dependent protein kinase (PKA), through prephosphorylation promoting 
downstream GSK-3β phosphorylation at multiple sites including Thr181, Ser199, 
Ser202, Thr205, Thr217, Thr231, Ser396 and Ser422 (Liu et al., 2006). 
Furthermore, additional modulation of tau phosphorylation by PKA is seen with 
cdk5 with promotion of phosphorylation at Ser396 (Liu et al., 2006). 
Dephosphorylation of tau is modulated by protein phosphatase 2A (PP2A), which 
promotes dephosphorylation at multiple Ser and Thr sites by binding the tau 
microtubule-binding domain (Sontag et al., 1996, Sontag et al., 1999). 
 
Under normal physiological conditions tubulin is present in over tenfold excess of 
tau, resulting in a large proportion of tau being microtubule bound (Iqbal et al., 
2010) with soluble tau recovered in the cytosol. However, this differs in AD brain 
where the protein is recovered in an additional two states, oligomeric and 
fibrillised (Kopke et al., 1993, Grundke-Iqbal et al., 1986, Bancher et al., 1989). 
Furthermore, the levels of total tau are increased four to eight times in AD, 
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stemming solely from the abnormally hyperphosphorylated form of the protein 
(Khatoon et al., 1992). Hyperphosphorylated tau does not retain the proteins 
normal function and cannot bind with tubulin or promote microtubule assembly. 
This form of tau both inhibits and disrupts microtubules (Alonso et al., 1994, Li et 
al., 2007), resulting in the sequestration of normal tau protein observed in 
diseased protein (Alonso et al., 1996, Alonso et al., 1994).  
 
In cases of advanced AD both hallmarks are always simultaneously present (Price 
and Morris, 1999), however the presence of neurofibrillary tangles has been 
shown to more strongly correlate with AD progression compared to amyloid 
plaque deposition. In early disease states neurofibrillary tangles have been shown 
to be present in the temporal lobe with no presence of amyloid plaques (Minati et 
al., 2009). It is also theorised that there is an intrinsic link between the production 
of amyloid plaques and neurofibrillary tangles with Aβ42 oligomers and plaques 
causing oxidation and impact upon cellular processes (Lloret et al., 2011) which 
in turn could initiate or accelerate the hyperphosphorylation of tau. 
 
2.1.1.3 – The Cholinergic and Glutamatergic Hypothesis  
As previously mentioned, in addition to typical pathological changes observed in 
AD there is an increasing consideration of the role of neurotransmitters in 
neurodegeneration. The neurotransmitter acetylcholine (ACh) is used by 
cholinergic neurons, where is has a role in both peripheral and central nervous 
systems (Ferreira-Vieira et al., 2016) and is supplied to most regions of the brain 
(Woolf and Butcher, 2011). The cholinergic system has been shown to have role 
in learning and memory including acquisition (Blokland et al., 1992) and in mice 
models, memory retrieval (Boccia et al., 2003). Studies have additionally shown 
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that there is significant loss of cholinergic neurons in dementia through the 
depletion of enzymes responsible for the generation and metabolism of ACh 
(Davies and Maloney, 1976) and that the loss of basal forebrain cholinergic 
neurons was associated with AD. These findings are the foundation for the 
cholinergic hypothesis of dementia, whereby the memory deficits noted in AD are 
related to the basal forebrain decline of the cholinergic system (Bartus et al., 
1982). 
 
Cholinergic synapses have additionally been shown to be affected by the key 
hallmark of AD, Aβ (Bell et al., 2006) in addition to a report of ACh and Aβ  
interaction promoting the initial formation of Aβ and its subsequent integration into 
Aβ -fibrils (De Ferrari et al., 2001). Furthermore, there is  a correlation in the 
severity of AD pathology and changes in synaptic transmission in the 
hippocampus (Selkoe, 2002).  
 
In addition to the involvement of ACh and cholinergic receptors in the progression 
of AD there is also a consideration for the role of excitatory neurotransmitter 
glutamate. The majority of CNS neurotransmission is mediated by both glutamate 
and its associated receptors, the ligand gated ionotropic glutamate receptors and 
the metabotropic second messenger coupled receptor which have a fundamental 
role in in the learning and memory function by maintenance of synaptic plasticity 
(Riedel et al., 2003). The main receptor group responsible for both the synaptic 
plasticity and function are the N-methyl-d-aspartate receptors (NMDAR) 
(Collingridge and Singer, 1990) through the enhancement of synaptic strength by 
a Ca2+/calmodulin-dependent protein kinase II signalling cascade (Wang and 
Reddy, 2017). Furthermore, NMDAR promotes neuronal survival through 
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suppression of the apoptosis pathway and allowing for survival gene expression 
by activation of cyclic-AMP response element binding protein (Wang and Reddy, 
2017). The sensitivity of NMDAR to calcium signalling has been attributed to the 
increased stimulation of glutamatergic signaling, and glutamate excitotoxicity. 
Whereby, prolonged increased levels of Ca2+ signaling results in neuronal death 
and subsequent impairment of cognition (Wang and Reddy, 2017). These findings 
highlight both ACh and glutamate as key targets to help build a wider 
understanding of AD pathology and as potential diagnostic tools with expanded 
use in the therapeutic approach to AD. 
 
2.1.1.4 – Treatment of Alzheimer’s Disease 
There is currently no cure for Alzheimer’s disease, and treatment is currently 
focused on the temporary management symptoms and behavioural changes. The 
only current FDA approved treatments used are Acetylcholinesterase (AChE) 
inhibitors to increase brain AChE levels and inhibit ACh turnover, compensating 
for the reduction in cholinergic neurons in AD (Rees and Brimijoin, 2003) or the 
NMDA-receptor antagonist memantine.   
 
However, there is a focus on targeted treatments for the hallmarks of AD, 
accumulation of Aβ plaques and hyperphosphorylated tau. For Aβ treatments 
have focused on targeting either the production or clearance of the peptide. Key 
targets include BACE1 and BACE2, where inhibition by verubecestat (MK-8931) 
has shown promise in clinical trials (Moraes and Gaudet, 2018). For tau 
therapeutic treatment options have been focused largely on PP2A stimulation and 
GSK-3β inhibition. The reversal of PP2A inhibition by memantine has been shown 
to decrease the hyperphosphorylation of tau (Mangialasche et al., 2010), while a 
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decrease in both tauopathy and in vivo tau lesions has been correlated with 
lithium inhibition of GSK-3β (Nakashima et al., 2005, Noble et al., 2005). 
 
However, in certain cases these targeted therapies have either shown little 
efficacy, failed at clinical trial or have normal physiological functions that if 
targeted could have adverse effects. This has highlighted the need for other 
options in both the field of treatment and diagnostics. Underlying these hallmarks 
and the symptomatic presentation of AD, metabolic balance and imbalance is 
perhaps the single most important and least understood parameter. With multiple 
metabolic processes are thought to be attributed to AD progression and include 
cellular stress, calcium overload, protein misfolding and dysregulated autophagy 
(discussed in Section 2: 1.2). Identifying key components in these processes may 
offer novel targets for both diagnosis and treatment, with the work highlighted in 
this thesis as focusing on the possible role of autophagy. 
 
2.1.2 – Autophagy 
Autophagy is the main pathway for the degradation of cytoplasmic components 
within the lysosome, to balance sources of cellular energy, during development 
and in response to nutrient stress (Glick et al., 2010). Three key types define this 
pathway; chaperone mediated autophagy (CMA), macro-autophagy and micro-
autophagy. In CMA protein translocation occurs through target and chaperone 
protein complex formation. This complex is recognised by lysosomal-membrane 
membrane protein 2A allowing for its transport across the membrane for unfolding 
and degradation to occur (Saftig et al., 2008). In micro-autophagy lysosomes 
directly take up cytosolic components through non-selective invagination of the 
lysosomal membrane (Glick et al., 2010). Macro-autophagy, henceforth referred 
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to as autophagy, however, is initiated by pre-autophagosomal structure formation, 
which through sequestration in the cytoplasm forming a double membrane-bound 
autophagosome (Axe et al., 2008). The autophagosome is involved in the 
formation of an autolysosome by fusion with the lysosome (Glick et al., 2010). 
Within the autolysosomes, acid hydrolases degrade the contained cellular 
components (Figure 1.2) (Galluzzi et al., 2014). Lysosomes are reformed 
following substrate digestion within the autolysosome, these lysosomes mainly 
contain lysosomal hydrolases and are smaller and less dense (Nixon, 2007). 
Through this mechanism autophagy maintains normal neural function through the 
removal of misfolded and aggregated proteins (Glick et al., 2010). This is applied 
directly to the generation and clearance of Aβ where autophagy is a key regulator 
(Nilsson and Saido, 2014). 
 
However, in AD this clearance is shown to be affected manifesting in Aβ 
aggregation. The multi-step process of autophagy opens possibilities for 
dysfunction to occur in the regulation, formation or clearance of the 
autophagosome, with evidence showing that dysregulation throughout the 
autophagy pathway can cause aggregate accumulation or ineffective aggregate 
clearance. In early AD there is believed to be an autophagosome imbalance which 
would affect later stage, downstream clearance of aggregates (Perez et al., 2015), 
supporting the theory that Aβ accumulation occurs in later disease states (Yang 
et al., 1998, Cataldo et al., 2000).  
 
Furthermore, increased levels of Aβ have been found in autophagic vacuoles 
highlighting that APP processing can take place, with additional reports stating 
that in AD brain there is autophagic vacuole accumulation in dystrophic neurites  














Figure 1.2 – Autolysosome formation in autophagy  
Cytosolic proteins and organelles are sequestered by an expanding phagophore (a, b), 
resulting in double-membrane vesicle formation (c), an autophagosome; the outer membrane 
of the autophagosome subsequently fuses with a lysosome (d), to expose the inner single 
membrane of the autophagosome to lysosomal hydrolases. The cargo-containing membrane 
compartment is lysed, and the contents degraded (e) (Xie and Klionsky, 2007) – Reprinted by 
permission from Springer Nature: Springer Nature, Nature Cell Biology (Xie and Klionsky, 
2007) (Autophagosome formation: core machinery and adaptations, Zhiping Xie and Daniel 
J. Klionsky [Copyright © 2019 Copyright Clearance Center, Inc. – Springer Nature (2007) 
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when compared to matched controls (Yu et al., 2005, Nixon, 2007). Additionally, 
the endosomal trafficking protein assembly, retromer has been shown to be 
deficient in AD resulting in inefficient clearance of autophagic vacuole during 
vesicular trafficking (Small and Petsko, 2015). 
 
Specific autophagy pathway proteins have also been shown to be dysregulated 
in AD, with the reduction in Beclin 1 compromising autophagosome formation in 
the inferior parietal lobe (Pickford et al., 2008, Rohn et al., 2011). Furthermore, 
Beclin 1 was shown to be critical in the accumulation of Aβ in mouse models, 
whereby depletion of the protein resulted in perturbation of clearance and 
formation of the autophagosome initiating the accumulation of both intracellular 
and extracellular Aβ (Pickford et al., 2008). 
 
Through the use of neuronal cell models our group have determined that cell 
signalling, and the autophagy pathway is impacted by leucine. As earlier 
indicated, autophagy is regulated through changes in nutrient cell signalling. 
Leucine, the substrate for hBCAT, controls the activity of the mechanistic target 
of rapamycin 1 (mTORC) complex (Figure 1.3). mTORC1 consists of five 
components; mTOR, regulatory-associated protein of mTOR (Raptor), GβL, 
PRAS40 and Deptor (Peterson et al., 2009). Under normal physiological 
conditions, activation of mTORC1 causes the phosphorylation of autophagy 
related protein 13 (Atg13), preventing the formation of the ULK1 kinase complex 
which inhibits the pathway (Hensley and Harris-White, 2015b). However, the 
regulatory effect that amino acids have on mTORC1 is abolished in deprived 
states leading to increased autophagy (Chen et al., 2014). During deprivation, 
ULK1 protein kinase is activated forming phagophores and inducing autophagy 
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(Chan et al., 2009). ULK1 activation involves beclin-1, the class-III 
phosphatidylinositol-III kinase (PI3K), VPS34, and microtubule-associated protein 
1 light chain 3 (Atg8/MAP1-LC3/LC3) or GABARAP homologs (Hensley and 
Harris-White, 2015a). 
 
LC3-II and VPS34 have been used as markers for autophagy due to their 
involvement in ULK1 activation and have been shown to associate with amyloid 
β and hyperphophorlylated tau aggregates in AD (Ma et al., 2010).  
 
2.1.3 - Function of the Branched Chain Amino Acids in the Brain 
The branched chain amino acids (BCAA), leucine (Leu), isoleucine (Ile), and 
valine (Val) are essential dietary nutrients that have a role in protein synthesis, as 
precursors for additional amino acids and the synthesis of brain neurotransmitter 
glutamate through their role as nitrogen donors (Yudkoff et al., 2005), and the 
synthesis of amine neurotransmitter serotonin and catecholamines; dopamine 
and norepinephrine (Fernstrom, 1990). Serotonin, dopamine and norepinephrine  
are derived from the aromatic amino acids (ArAA) tryptophan (Trp), phenylalanine 
(Phe) and tyrosine (Tyr) (Fernstrom, 1990).  
 
Dietary intake of BCAAs comes largely from dietary animal-based proteins which 
have between 15-20% amino acid content (U.S. Department of Agriculture, 2004).
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Figure 1.3 - Regulation of autophagy by nutrients and hormones via the mammalian 
target of rapamycin (mTOR) signalling pathway. 
 (A) Activation of the ULK1/2 protein kinase complex including the autophagy related proteins 
and the 200 kDa focal adhesion kinase family-interacting protein (FIP200) are involved in the 
initial induction of the autophagosome. This is followed by a class III phosphatidylinositol 3-
kinase or human vacuolar protein sorting 34 (hVps34), complexed with BCL-2 interacting 
moesin-like coiled-coil protein 1 (Beclin 1) and Vps15 dependent nucleation step. Beclin 1 is 
involved in two recruitment complexes, the Atg14L and UV radiation resistance-associated 
gene (UVRAG) complex, which are required for phagophore formation and phagocytosis, 
respectively. Elongation and closure of the autophagosome requires several Atg proteins, 
hVps34 and microtubule-associated light chain 3 phosphatidylethanolamine (LC3), which is 
regulated by GTPase Rab5. The outer membrane of the autophagosome then fuses with a 
lysosome, exposing the inner single membrane to lysosomal hydrolases whereby the contents 
are degraded. (B) Hormones and growth factors such as insulin and insulin-like growth factor 
(IGF-1) trigger mTORC1 activity through a cascade of events resulting in recruitment and 
activation of Akt which induces phosphorylation and degradation of tuberous sclerosis 
complex protein 2 (TSC2). TSC2 degradation permits GTP-bound Rheb to directly interact 
and activate mTORC1. The Ras-ERK pathway also activates mTORC1 through inhibitions of 
TSC1 and TSC2. (C) Amino acids, in particular leucine, regulate the mTORC1 through the 
Rag complex (Ras-related GTPase), which recruits mTOR to the lysosomes with Rheb and 
hVps34. (D) Inhibition of the amp-activated protein kinase signaling pathway is triggered by 
high glucose levels, resulting in the decrease of AMP:ATP ratio that inhibits TSC1 and TSC2, 
activating mTORC1 and inhibiting autophagy. 
Reproduced under the Creative Commons License - Copyright © 2017 Shafei, Harris and 
Conway Frontiers in Aging Neuroscience (Shafei et al., 2017) 
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More than 60% of ingested BCAAs are primarily metabolised extrahepatically by 
skeletal muscle (Gelfand et al., 1986), a portion of the remaining percentage enter 
systemic circulation, increasing blood BCAA levels (Platell et al., 2000).  
Peripheral BCAAs are transported into the brain across the blood brain barrier 
through preferential binding to the large neutral amino acid transporter (LAT1) on 
the central nervous system endothelial cell layer (Boado et al., 1999). LAT1 
transporters are almost fully saturated at normal plasma amino acid 
concentrations (Fernstrom, 2005), and are competitively shared by large neutral 
amino acids (LNAAs) which include tryptophan, tyrosine and phenylalanine 
(Fernstrom, 2013). Ingestion of BCAAs and LNAAs alters the uptake by LAT1 
transporters. Increases in BCAA plasma or serum concentration cause LAT1 
uptake of LNAAs to decrease, as shown by a fall in brain tryptophan 
concentrations following an injection of Ile, Leu or Val (Carlsson and Lindqvist, 
1978, Fernstrom, 2013). Additionally, increases in plasma or serum LNAAs will 
alter the uptake of the other amino acids. Through this mechanism 
neurotransmitter levels in the brain can be altered, as evidenced by increases or 
decreases in serotonin synthesis following either tryptophan or LNAA injection, 
respectively resulting in altered neuronal serotonin release (Gartside et al., 1992, 
Sharp et al., 1992). 
 
Through competitive transport by LAT1 the BCAAs enter the brain and are 
metabolised by the human branched chain aminotransferase (hBCAT) proteins, 
which are predominantly present as two isoforms, the cytosolic (hBCATc) and 
mitochondrial (hBCATm). The hBCAT proteins are responsible for the 
transamination of; Leu, Ile and Val with α-ketoglutarate (Hutson, 2001) resulting 
in the release of their respective branched chain α-keto acid (BCKA). The 
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transamination of the BCAAs supplies nitrogen to α-ketoglutarate for essential 
neurotransmitters glutamate and glutamine synthesis (LaNoue et al., 2001).  
 
The committed, rate limiting step in the oxidation of BCAAs is catalysed by the 
second enzyme in the catabolic pathway, the branched-chain alpha-keto acid 
dehydrogenase complex (BCKDC) (Brautigam et al., 2006). BCKDC is involved 
in the irreversible oxidative decarboxylation of the branched chain α-keto acids 
into co-enzyme A derivatives (Chuang et al., 2006, Hull et al., 2015). The BCKD 
complex is composed of the three catalytic subunits; a branched chain α-keto acid 
decarboxylase (E1), a dihydrolipoyl transacylase (E2), and a dihydrolipoyl 
dehydrogenase (E3) (Harris et al., 1997). At times where BCAAs are required for 
protein synthesis the BCKD complex is inactivated by branched chain alpha-keto 
acid dehydrogenase kinase (BDK) through covalent modification and 
phosphorylation of E1α subunits (Murakami et al., 2005). Reactivation of the 
complex occurs, when BCAAs are in excess, through dephosphorylation by 
branched-chain phosphatase (Harris et al., 2005). 
 
In the brain, glutamate is a major excitatory neurotransmitter and the precursor to 
the major CNS inhibitory neurotransmitter gamma-aminobutyric acid (GABA) 
synthesis.  Due to the significant impact that BCAA metabolism has on glutamate 
regulation, previous studies in this research group have mapped the hBCAT 
proteins to all areas of the human brain where hBCATc was solely expressed in 
neurons that were either GABAergic or glutamatergic (Hull et al., 2012). Mapping 
of hBCATc showed significant distribution within the hippocampal region of the 
brain in neuronal cell bodies, implying that metabolism of BCAAs primarily 
contributes to the glutamate metabolic pool, rather than the excitatory glutamate 
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pool. Conversely, hBCATm was mapped throughout the vascular endothelial 
layer, demonstrating that transamination can occur in this cell type, indicating that 
hBCATm has a role in glutamate regulation (Hull et al., 2012). Further 
investigation of hBCATs in AD brain has shown that expression of these proteins 
is increased in the frontal and temporal cortex in addition to the hippocampal 
region with the mitochondrial form exhibiting a 170% increase in the level of BCAT 
(Hull et al., 2015). This finding correlated with Braak staging, the method by which 
the degree of AD pathology can be classified based on the distribution pattern of 
neurofibrillary tangles (Braak and Braak, 1991), and suggested a direct link 
between hBCAT levels and disease severity, and that the metabolic pathways 
regulated by these proteins are perturbed in AD (Hull et al., 2015). 
 
The levels of the neurotransmitter glutamate have a significant effect on protein 
expression and neurotoxicity. Under normal physiological conditions glutamate is 
essential for memory and learning, and has a role in dendrite and synapse 
formation (Trotti et al., 2001) however, neurotoxicity can occur when extracellular 
glutamate levels rise at the synapses (Mattson and Chan, 2003). Increased levels 
of glutamate have been reported to cause short term physiological changes to 
neurones and neuronal degeneration in instances of extended exposure (Choi, 
1985).
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Figure 1.4: Transport of branched chain amino acids across the blood brain barrier and the function of hBCAT in branched chain amino acid 
metabolism.  
Peripheral BCAA’s isoleucine, leucine and valine are transported into the brain across the blood brain barrier through preferential binding to the large neutral 
amino acid transporter (LAT1) on the central nervous system endothelial layer. In the brain hBCAT catalyses the reversible transamination of BCAA’s with α-
ketoglutarate resulting in the release of their respective branched chain α-keto acid. The transamination of the BCAAs supplies nitrogen to α-ketoglutarate for 
essential neurotransmitters glutamate and glutamine synthesis. Figure created using Servier Medical Art.
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The excessive release of glutamate additionally causes an intracellular influx of 
Ca2+ ions through the activation of postsynaptic membrane receptors (Sattler and 
Tymianski, 2000). The postsynaptic effect of glutamate is mediated by the 
ionotropic N–methyl-D-aspartate (NDMA), kainite and 2-amino-3-(3-hydroxy-5-
methylisoxazol-4yl) propionate receptors (Hollmann and Heinemann, 1994), with 
NDMA associated with calcium dependent changes due to high Ca2+ permeability 
(Choi, 1988). Enhanced activation causes an influx of calcium ions disturbing the 
cellular environment and activating intracellular Ca2+ dependent signalling with 
the final result being neuronal cell death (Sattler and Tymianski, 2000). The 
calcium ion influx caused by excessive NDMA activation additionally activates 
neuronal NO synthase and generates reactive oxygen species (ROS) (Garthwaite 
et al., 1988). The overproduction of ROS and NO free radicals contributes to cell 
death (Lipton and Rosenberg, 1994), and protein aggregation, indicative of 
neurodegenerative disease, nitrosative/oxidative stress causing post-translation 
changes to proteins (Zhang and Kaufman, 2006). The observed metabolic 
changes in AD have an impact on brain neurotransmitter levels, which result in 
the cognitive impairment of AD. These impairments can range between the early 
clinical symptoms of depression to impaired communication, disorientation and 
behavioural changes in later stage disease (Alzheimer's, 2015). 
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2.1.3.1 – Branched Chain Amino Acids in Disease 
Serum BCAA levels are altered in several neurological disorders. Increased and 
toxic levels of BCAA and branched chain α-keto-acids are observed in maple 
syrup urine disease (Menkes, 1962). Symptoms at clinical presentation include 
neurological dysfunction and seizures, in some cases resulting in infant death 
(Chuang et al., 2006, Chuang and Chuang, 2000). Conversely, in traumatic brain 
injury (TBI) the serum amino acid profile show reduced levels of BCAAs and 
increased ArAAs, with excessive glutamate release following the initial injury 
(Vuille-Dit-Bille et al., 2012). Changes in net synaptic efficacy and neuronal 
destruction, similar to that reported in AD occurs, with damage to the limbic 
hippocampus also observed. This contributes to cognitive impairment and a 
regional shift in network excitability in both the CA1 and dentate gyrus (Witgen et 
al., 2005), areas which have been shown to dye heavily populated by hBCATc 
labelled neurones (Hull et al., 2015), which contribute to glutamate production. 
 
2.1.3.2 - Branched Chain Amino Acid Supplementation 
Amino acid supplementation has been trialled with respect to improving cognition 
in conditions which present with deregulated glutamate levels. Supplementation 
with BCAAs in TBI models, brain injured mice, showed improved cognition and 
restored synaptic ability (Cole et al., 2010). In these models, expressional 
changes for BCATc, BCKDC, glutamate dehydrogenase and glutamic acid 
decarboxylase were induced post-trauma suggesting a role for BCAA and 
neurotransmitter metabolism disturbance in this model. Additional investigation 
has shown new findings for the role of BCAA supplementation to improve 
cognition and in some cases improved recovery from a vegetative or minimally 
conscious state (Aquilani et al., 2008). In patients with hepatic encephalopathy, 
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where similar amino acid profiles to TBI are observed, supplementation with 
BCAA restored their Fischer ratio (ratio BCAA relative ArAA) to normal (Itou et al., 
2009). The altered BCAA and ArAA profile from these reports indicate how 
changes in BCAA metabolism can impact neurotransmitter synthesis and how 
supplementation can correct these changes. It is therefore important to 
understand how serum BCAA levels influence brain glutamate in AD models and 
more importantly if supplementation can alleviate the potential dysregulation. 
 
Summary 
The limited knowledge of the metabolic imbalances that present in AD, and 
involvement of BCAAs, in particular leucine, offer an important diagnostic and 
prognostic factor. Diagnosis of MCI and the determination of those who will 
develop AD is currently dependent on clinical assessment and cognitive ability 
testing, with no guarantee of accurately determining a patient’s prognosis. 
Understanding the role and profile of the BCAAs in both MCI and AD offers and 
will enable earlier and more accurate diagnostic and prognostic assessment. 
Additionally, BCAAs supplementation have been shown to improve cognition in 
neurological conditions where glutamate levels are deregulated, as seen in AD. 
This work aimed to expand the understanding of the role of leucine deprivation 
and supplementation on glutamate levels, and further explore the role of leucine 
in autophagy and metabolism. 
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Chapter 2 – Aims and Objectives 
 
2.1 – Hypothesis 
The hypothesis for this research is that extracellular leucine directly regulates 
glutamate levels, and that deprivation contributes to glutamate toxicity and protein 
aggregation, hallmarks of AD pathology. Moreover, the concentration of the 
BCAAs will be significantly lower in patients with AD relative to controls and will 
progressively decrease from the early onset of MCI to progressive disease forms.  
 
2.2 – Aim One 
To develop a liquid chromatography tandem mass spectroscopy method for the 
analysis of serum amino acids, to establish an amino acid ‘signature’ profile for 
patients with AD and monitor the BCAA profile in the serum of patients with MCI. 
These finding will be correlated with brain imaging using MRS and cognitive 
assessments 
 
2.3 - Aim Two 
To investigate the impact of leucine deprivation on cellular amino acid levels, 
metabolism and markers of autophagy.  
 
2.3 - Aim Three 
To investigate the effect of short-term and long-term supplementation on 
reversing leucine-deprived autophagy and balancing glutamate in AD models. 
  
Fred Hudd | 2020 
 39 
Fred Hudd 
REGULATION OF NEUROTRANSMITTER SYNTHESIS IN ALZHEIMER’S DISEASE – 
POTENTIAL FOR NOVEL DISEASE BIOMARKERS | 2019 
Chapter 3 
MATERIALS AND METHODS 
Fred Hudd | 2020 
 40 
Chapter 3 – Materials and Methods  
 
3.1 - Materials 
 
The following materials were obtained from the listed manufacturers. 
 
Abcam plc 
Address: Discovery Drive, CB2 0AX, Cambridge, United Kingdom 
Materials: Ab7291 - Alpha-Tubulin Mouse Antibody 
 
 
Agilent Technologies UK Limited 
Address: Winnersham Triangle, RG41 5DZ, Wokingham, United Kingdom 
Materials: 5182-0716 - Vial, screw top, amber, write-on spot, certified, 2 mL, 
100/pk, 5182-0717 - Cap, screw, blue, PTFE/red silicone septa, 100/pk, 959993-
902 - ZORBAX Eclipse Plus 95Å C18, 4.6 x 150 mm, 5 µm, 103015-100 - 
Seahorse XF Cell Mito Stress Test Kit, 102340-100 Seahorse XFe24 FluxPaks, 
103577-100 – Seahorse XF 1 M Glucose Solution, 103579-100 Seahorse XF 200 
mM Glutamine Solution, 103578-100 Seahorse XF 100 mM Pyruvate Solution.  
 
 
CK Isotopes Limited 
Address: Desford, LE9 9FL, Leicestershire, United Kingdom 
Materials: DLM-3725-0.5 - L-Glutamic Acid (2,4,4-D3, 97-98%), DLM-141-0.1 - L-
Isoleucine (D10, 98%), DLM-1259-1 – L-Leucine (5,5,5-D3, 99%), DLM-1258-1 – 
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L-Phenylalanine (Ring-D5, 98%), DLM-451-0.5 – L-Tyrosine (Ring-D4, 98%), 
DLM-488-0.5 – L-Valine (D8, 98%) 
 
 
Eurofins Genomics Germany GmbH 
Address: Anzigner Str. 7a, 8556, Ebersberg, Germany  
Materials: Custom oligonucleotides (Section 3.3 – Table 3.3.1) 
 
 
Fisher Scientific Ltd 
Address: Bishop Meadow Road, LE11 5RG, Loughborough, United Kingdom 
10001334 - Acetonitrile, Optima™ LC/MS Grade, Fisher Chemical, 10505904 - 
Water, Optima™ LC/MS Grade, Fisher Chemical, 10188164 - Water with 0.1% 
Formic Acid (v/v), Optima™ LC/MS Grade, 26623 - Spectra™ Multicolour Broad 
Range Protein Ladder, NP0002 - NuPAGE™ MES SDS Running Buffer (20X), 
61965059 - DMEM, high glucose, GlutaMAX™ supplement, A3160802 - Fetal 
Bovine Serum, qualified, One Shot™ format, Brazil, K0781 - Thermo 
Scientific™ GeneJET™ Whole Blood Genomic DNA Purification Mini Kit, 
10338442 - Invitrogen™ Novex™ NuPAGE™ 4-12% Bis-Tris Protein Gels, 
1.0mm, 15 well, Thermo Scientific™ 10X TBE Buffer (Tris-borate-EDTA), 




hBCATc and hBCATm Custom Synthesised Antibodies 
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New England BioLabs (UK) Ltd 
Address: 75-77 Knowl Piece, SG4 0TY, Hitchin, United Kingdom 
 
R0139S – HhaI (20000 units/ml), N3233S - Low Molecular Weight DNA Ladder 
(500 µg/ml)  
 
Cell Signalling Technologies antibodies – Beclin-1, mTOR and Phospho-mTOR 
were obtained from New England BioLabs. 
 
 
Sigma Aldrich Co 
Address: The Old Brickyard, New Road, SP8 4XT, Gillingham, United Kingdom 
 
D9443-500ML Dulbecco’s Modified Eagle’s Medium – Low Glucose (SILAC), 
LAA21-1KT – L-Amino Acids, GE10600003 - Amersham™ Protran® Premium 
Western blotting membranes, nitrocellulose pore size 0.45 µm, roll W × L 300 mm 
× 4 m, WHA7141104 -Whatman® nitrocellulose membrane filters white gridded, 




Address: 610 Centennial Park, Centennial Avenue Elstree, WD6 3TJ, Hertz, 
United Kingdom  
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186003038 - XBridge BEH Shield RP18 Column, 130Å, 3.5 µm, 2.1 mm X 150 
mm, 1/pkg, WAT097958 - 2.1x1 mm Holder Kit for Cartridges and Guard 
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3.2 - Antibodies 
Antibodies were used at the concentrations listed below and obtained from the 
respective suppliers. 
Antibody Source Dilution Supplier Code 
Alpha-tubulin Mouse 1:5000 Abcam plc Ab7291 
Beclin-1 Rabbit 1:1000 Cell Signalling Technologies 3738S 
hBCATc Rabbit 1:3000 Insight Biotechnology 
Custom 
Synthesis 
hBCATm Rabbit 1:3000 Insight Biotechnology 
Custom 
Synthesis 
MAP LC3β Mouse 1:500 Santa Cruz SC-376404 
mTOR Rabbit 1:1000 Cell Signalling Technologies 2972S 
P-mTOR (S2448) Rabbit 1:1000 Cell Signalling Technologies 2971S 
Alexa Fluor 568 
Secondary (Anti-Rabbit) Goat 1:500 Invitrogen 10544773 
 
3.3 - Primers: 
 
Primer Sequence 
ApoE Upstream 5’-TCC AAG GAG CTG CAG GCG GCG CA-3’ 
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3.4 - Ethical Statement and Participants 
The study was approved by North Somerset and South Bristol Research Ethics 
Committee, Bristol, UK. All experiments were carried out in accordance with 
ethical and NHS governance guidelines and approvals. University of Bristol agree 
in principle to anonymised data sharing with external researchers and each data 
request is assessed individually. Participants with the capacity to consent were 
recruited from the following local and national volunteer registers: Join Dementia 
Research, BRACE charity, Avon and Wiltshire Mental Health Partnership Trust, 
ReMemBr group research database and North Bristol NHS Trust. A total of 118 
participants were recruited, where 71 were healthy aged individuals and 30 
people had a recent diagnosis of MCI (both amnesic and multi-domain MCI) and 
17 people with a diagnosis of probable AD. MCI was diagnosed at the Dementia 
Research Clinic and other local memory services using standard criteria and, for 
inclusion, all MCI had to have had memory complaints and/or score more than 1 
SD below expected for age on a test of memory. Inclusion criteria: All participants 
had capacity to consent to research and were either drug-free or on stable 
treatment. In summary: 1) Patients diagnosed with Alzheimer's disease with a 
Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment 
(MoCA) score of greater than 10/30 and have memory deficits demonstrated on 
at least one of their clinical cognitive assessments. 2) Patients diagnosed with 
MCI who have either symptoms of amnesia or >1 SD impairment below expected 
for age performance in episodic memory clinical cognitive tests. 3) Healthy 
participants age-matched to patients above. Exclusion criteria 1) patients with 
dementia likely to be of a different aetiology; 2) participants taking medication 
likely to interfere significantly with cognitive function (except cholinesterase 
inhibitor and memantine used routinely in dementia) 3) participants with physical 
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limitations such that they will not be able to carry out the requirements of the 
study; 4) participants with a history of significant claustrophobia or previous panic 
or claustrophobia while in an MRI scanner; 5) participants with significant other 
neurological or psychiatric illnesses likely to interfere with performance on the 
task. All participants underwent a screening interview to assess demographic 
factors thought to impact on cognitive decline (IQ, history of head trauma, 
epilepsy, smoking and alcohol intake) (Table 1). There was no significant 
difference between AD, MCI and control groups with respect to most parameters, 
however, there was a significant difference with respect to years of education and 
IQ score. For blood analysis a number of people were unable to provide a sample, 
therefore a total of 46 controls, 17 MCI and 15 AD were recruited for this aspect 
of the study. 
 
3.5 - Methods 
 
3.5.1 - Cognitive Assessment of Control, MCI and AD 
A battery of assessments designed to probe hippocampal function as well as tests 
of wider cognitive function was implemented (Conducted by The ReMemBer 
group at The University of Bristol). Tests that were performed as part of the 
experimental procedure included: 1) Montreal cognitive assessment (MoCA, as a 
global cognitive screen). 2) Paired Associate Learning from CANTAB as a 
pattern/spatial memory task widely used and thought to be a "hippocampal" task 
- used as an early marker of AD. 3) Adapted verbal learning task (similar to 
Hopkins Verbal Learning Task) testing memory over 30 minutes, 24 hours, 2, 7 
and 14 days (Dillon et al., 2017). 
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3.5.2 – Magnetic Resonance Imaging (MRI) of Control, MCI and AD 
MRI imaging was performed at the Clinical Research and Imaging Centre (CRiC 
Bristol), University of Bristol. 
 
All participants were scanned using a Siemens Magnetom Skyra 3T MRI system 
using a 32Ch head coil. The MRI protocol was as follows: 3D T1-weighted MRI 
was collected with MPRAGE: coronal, TR 2200 ms, TE 2.42 ms, TI 900 ms, flip 
angle 9°, resolution 0.34 x 0.34 x 1.60 mm3 (after 2-fold interpolation in-plane), 
matrix size 540 x 640 x 144 (after 2-fold interpolation in-plane), GRAPPA factor 
2, time 5:25. Quantitative T2 images were acquired with a multi-contrast spin-
echo sequence: coronal, TR 4500, TE 12 ms, number of echoes 10, echo spacing 
12 ms, resolution 0.34 x 0.34 x 1.7 mm3 (after 2-fold interpolation in-plane, and 
inclusive of 15% slice gap), matrix size 540 x 640, 34 slices, GRAPPA factor 2, 
time 11:07. 
 
Total brain, gray matter, white matter and CSF space volumes were determined 
using FSL routines (http://www.fmrib.ac.uk/fsl). Morphometry of hippocampus 
and its sub-regions were determined from T2 images using the manual protocol 
by (Wood et al., 2015). This protocol provides volumes for 6 subfields as follows: 
CA1, CA2, CA3, dentate gyrus, subiculum and lumped stratum moleculare, 
stratum lacunosum and stratum radiatum (SM/SL/SR). 
 
3.5.3 – Blood Biomarkers for Control, MCI and AD 
Whole blood samples were provided by participants grouped into control, 
presentation of Alzheimer's disease or mild cognitive impairment. Samples were 
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fractionated by centrifugation at 1,300 x g for 10 minutes at 4°C. Serum was 
aliquoted and subsequently stored at -80°C until analysed.  
 
3.5.5 - Protein Estimation Using the Amido Black Assay 
A purified BSA protein standard was prepared to a concentration of 0.1 µg/µL and 
diluted to produce a standard curve (0, 1, 2.5, 5, 7.5, 10, 12.5, 15, 17.5 and 20 
µg). Unknown samples were diluted to a concentration approximately within the 
range of the standard curve with 18 MΩ water. For all samples, 30 µL of Tris-HCl 
buffer (1M trichloroacetic acid, 35 mM sodium dodecyl sulphate, pH 7.4) and 60 
µL of 60% trichloroacetic acid were added and the samples incubated at room 
temperature for 5 minutes. Samples were pipetted onto a 0.45 µm nitrocellulose 
membrane periodically hydrated with 6% trichloroacetic acid and pulled through 
under gentle vacuum (16.9 kPa). The membrane was subsequently stained in 
staining buffer (1g/L Amido black powder, 45% methanol, 10% acetic acid in 
diH2O) for 2 minutes, washed with diH2O and destained in buffer (90% methanol, 
2% acetic acid in diH2O) for 1 minute. Destaining was repeated to remove excess 
background staining and protein spots excised from the membrane and incubated 
in eluent (25 mM sodium hydroxide, 50 µM ethylenediaminetetraacetic acid, 50% 
ethanol in diH2O) for 10-20 minutes. Eluent absorbances were measured at 620 
nm using a FLUOstar Omega microplate reader (BMG Labtech). Samples 
concentration was calculated against the BSA standard curve.  
3.5.6 - Wet Transfer Western Blot Analysis 
Serum samples were diluted to a concentration of 10 µg in LDS sample buffer 
(4x) with 5% β-mercaptoethanol and denatured at 95°C for 10 minutes. Samples 
were vortexed and centrifuged prior to loading onto a 4-12% Bis-Tris gradient gel. 
Proteins were separated in parallel with broad range ladder at 150 V for 1 hour in 
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MES electrophoresis buffer. The proteins were then transferred overnight onto a 
PVDF membrane at 50 V in transfer buffer (20% methanol, 25 mM Tris, 190 mM 
glycine, pH 8.3). The membrane was washed in TBST (0.1% Tween, 200 mM 
NaCl, 2 mM Tris, pH 7.5) and subsequently blocked with 5% BSA in TBST for 1 
hour. Primary antibody was prepared in 5% BSA (1:1000 for hBCATc and 
hBCATm) and added to the membrane for 1 hour. Several washes in TBST were 
performed and the membrane incubated for a further 1 hour with appropriate 
dilutions of HRP-linked secondary antibody. After further washes the positive 
bands were visualised with chemiluminescent HRP substrate on an Odyssey® Fc 
Imaging System (LI-COR Biosciences) and results normalised against the 
appropriate loading controls. 
 
3.5.7 - 1D Gel Electrophoresis 
Serum samples were diluted to a concentration of 5 µg in LDS samples buffer 
(4x) with 5% β-mercaptoethanol. Samples were treated and separated in the 
same manner detailed in Wet Transfer Western Blot. Gels were subsequently 
stained with InstantBlue Coomassie Dye and incubated at room temperature for 
1 hour on a rocking mixer. After 1-hour gels were washed in deionised water and 
imaged using an Odyssey® Fc Imaging System (LI-COR Biosciences).  
 
3.5.8 - ApoE Genotyping 
Genomic DNA was extracted from whole blood or lysed white blood cells using a 
GeneJET Whole Blood Genomic DNA Extraction Kit. Two hundred microlitres of 
whole blood or WBC were aliquoted and 20 µL of proteinase K and 400 µL of lysis 
buffer added. Samples were mixed by vortex and incubated at 56°C for 10 
minutes in a thermo mixer at 1000 RPM. Subsequently, 200 µL of 100% ethanol 
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was added, the sample transferred to a GeneJET spin column and centrifuged for 
1 minute at 6,000 x g. The flow through was discarded and 500 µL of Wash Buffer 
I added before centrifuging for 1 minute at 8,000 x g. The flow through was once 
again discarded, 500 µL of Wash Buffer II added and the column centrifuged 
again at 17,000 x g for 3 minutes. The column was subsequently transferred to a 
new collection tube and 200 µL of elution buffer added. The column was incubated 
in elution buffer for 2 minutes at room temperature before being centrifuged at 
17,000 x g for 2 minutes. Eluted DNA was stored at -20°C.  
 
3.5.9 - PCR Amplification of ApoE Coding Region 
The ApoE coding region of extracted genomic DNA was amplified by PCR using 
oligonucleotide primers (Eurofins Genomics; upstream primer: 5ʹ- TCC AAG GAG 
CTG CAG GCG GCG CA -3ʹ, downstream primer: 5ʹ- ACA GAA TTC GCC CCG 
GCC TGG TAC ACT GCC A - 3ʹ). The PCR mix consisted of 10 µL of GC Taq 5x 
buffer, 2 µL of ApoeE23 and ApoE31 primers (2 pmol), 2 µL of dNTPs mix, 0.2 µL 
of One Taq polymerase and made to a final volume of 50 µL with nuclease free 
water. Amplification was performed in an PTC-200 Peltier Thermal Cycler. 
 
3.5.10 - HhaI Restriction Digest 
PCR product was digested with HhaI restriction enzyme, 26 µL of product was 
added to 1 µL of HhaI and 3 µL of NEB CutSmart Buffer (10x). The solution was 
incubated at 37°C overnight in a thermomixer.  
 
3.5.11 – Visualisation of HhaI Digested Products 
HhaI digested PCR products were visualised on a 2.5% Metaphor agarose gel 
supplemented with ethidium bromide at 2.5%. Samples were separated at 80v for 
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2 hours in TBE buffer and imaged using an Odyssey® Fc Imaging System (LI-
COR Biosciences). 
 
3.5.12 - Preparation of Amino Acid Standards and Calibrators 
Powdered amino acid standards for glutamic acid, isoleucine, leucine, 
phenylalanine, tyrosine and valine were used to prepare individual 1 mM stock 
solutions in 0.1% formic acid in water and stored at -80°C until required. 
Deuterium labelled isotope internal standards for each amino acid were prepared 
in the same manner and combined and diluted to a concentration of 500 µM. 
Mixed amino acid calibrators of 1 µM, 5 µM, 10 µM, 20 µM, 30 µM, 40 µM, 50 µM, 
60 µM, 70 µM, 80 µM, 90 µM and 100 µM were prepared by dilution with 0.1% 
formic acid in water and the addition of 50 µM internal standard. 
3.5.13 - Serum and Fluid Sample Preparation 
Serum samples were thawed unassisted at room temperature and vortexed 
before analysis. One hundred microlitres was added to 350 µL of 0.1% formic acid 
in acetonitrile and 50 µL of mixed deuterium labelled internal standard to give a 
final concentration of 50 µM. Samples were vortexed and centrifuged at 3,200 g 
for 10 minutes at room temperature. Fifty microlitres of supernatant was aliquoted 
into sample vials and evaporated to dryness under a stream of nitrogen gas. The 
sample residue was reconstituted in 200 µL of 0.1% formic acid in water.  
 
3.5.14 – Cell Sample Preparation 
SH-SY5Y cells were grown to confluence and treated before the media was 
removed and the cells washed with ice cold PBS. Cells were subsequently 
extracted by scraping in RIPA buffer (10 mM Tris, 150 mM NaCl) with protease 
inhibitor cocktail.  Cells were incubated in RIPA buffer for 30 minutes before 
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sonication for 2 minutes (10 seconds on, 10 seconds off) at 10 microns. Lysates 
were clarified by centrifugation at 13,000 x g for 10 minutes and the supernatant 
aliquoted into separate tubes and stored at -80 until required. Cell media was 
filtered through a 0.45 µM membrane to remove any remaining cells and stored 
at -80. Both cell lysates and media were prepared for analysis in the same manner 
as serum samples.  
 
3.5.15 - Determination of Precursor Ions 
Mass spectrometry scanning was used to determine each amino acid and labelled 
isotopes precursor ion value. Ten microlitre of sample was analysed with no 
chromatographic separation. Samples were positively ionised by an electrospray 
ionisation source with Agilent JetStream technology. Nitrogen was used as both 
nebuliser and collision gas at a pressure of 45 psi, with sample injection time set 
to 0.50 minutes. Ion mass was analysed between a detection range of 100-300, 
at a fragmentor voltage of 135 V and cell accelerator voltage of 4 V.  
 
3.5.16 - Determination of Product Ions 
Product ion transitions were determined through the use of the Agilent 
MassHunter Optimiser program (Ver. B.07.01 Build. 7.1.7112.0). Precursor ion 
values were input from previous mass spectroscopy data and optimised for amino 
acid mass with the addition of a single hydrogen atom. Ten microlitres of 1 mM 
amino acid and internal standard stock solution was analysed and precursor ion 
intensity optimised through automated alteration of fragmentor voltage. Tandem 
mass spectroscopy was used to determine the most suitable product ions, and 
detection sensitivity optimised through automated alteration of collision energy. 
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3.5.17 - Optimisation of Acquisition Parameters 
Acquisition parameters for the source were optimised using Agilent 
MassHunter Source Optimiser and iFunnel software. Flow dependent 
parameters (nebuliser pressure, drying gas temperature and flow rate, sheath 
gas flow (SGF)), and compound dependent parameters (capillary voltage 
(CV), sheath gas temperature (SGT) and nozzle voltage (NV)) were optimised 
through the injection of 10 µL of 1 mM mixed amino acid and internal 
standard. Spectral count and abundance were monitored for beneficial 
alterations for each amino acid and internal standards product ion. 
 
3.5.18 - Sample Analysis for Branched Chain and Aromatic Amino Acids 
Chromatographic separation was performed using an Agilent 1260 Series LC 
system, coupled with an Agilent 6460 triple quadrupole mass spectrometer for 
tandem mass spectroscopy and multiple reaction monitoring. Sample was 
injected at onto an Agilent ZORBAX Eclipse Plus C18 column (4.6 mm x 150 mm, 
5 µm) maintained at 20°C. Glutamic acid, isoleucine, leucine, tyrosine and valine 
were eluted with a mobile phase of 0.01% formic acid in water – acetonitrile (98:2). 
Phenylalanine was eluted with a mobile phase of 0.01% formic acid in water – 
acetonitrile (80:20). Mobile phase was set to a flow rate of 0.3 mL/minute for all 
analysis. For all sample runs blanks of 0.1% formic acid were injected between 
triplicate sample runs and the system and column cleaned with 80% acetonitrile 
after 5 sample runs.  
 
Sample data was analysed with Agilent MassHunter Quantitative Analysis and 
Qualitative analysis software (Ver. B.07.00 Service Pack 1) and normalised 
against total protein for each sample.  
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3.5.19 - Percentage Recovery 
Serum, cell samples and prepared amino acid standards were spiked with a 
50 µM mixed amino acid in 0.1% formic acid in water and prepared in the 
same manner as analysis samples without the addition of an internal standard 
before drying. Dried samples were reconstituted in 200 µL of mixed deuterium 
labelled internal standard and analysed in the same manner as participant 
samples.  
 
3.5.20 – Sample Stability 
Serum amino acid stability when stored at -80°C was assessed over a three-
month and six-month period from sample collection. Samples were analysed 
as described in 3.5.17 upon collection with subsequent analysis three and six 
months after this date. Intra-run and total coefficients of variation were 
calculated for each run. 
 
3.5.21 - Statistical Analysis 
The data was screened for its accuracy and validity and for any potentially 
influential or outlying observations which may otherwise unduly impact results. A 
between-participants analysis of variance for a one-way design, with a post-hoc 
application of Tukey’s HSD pairwise test was used to assess for differences 
between Control/MCI/AD for BCATc, BCATm, amino acids, brain sub-volumes, 
and the cognitive data. Residuals under each ANOVA were examined to ensure 
they did not grossly deviate from the assumption of errors being independent 
identically distributed normal deviates. Pearson’s correlation coefficient was used 
to assess the strength and direction of correlations between quantitative 
measures. 
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MoCA scores were used in a linear discriminant analysis to develop a baseline 
model to discriminate between Control/MCI/AD. We sought to extend this 
baseline model to determine whether the inclusion of BCATc, BCATm, the amino 
acids and brain sub-volumes would improve the discrimination between groups. 
Accuracy of discrimination was determined using leave-one-out cross-validation. 
To account for the putative ordering of outcome (Control/MCI/AD) we further used 
MoCA scores in an ordinal logistic regression model. We sought to extend this 
baseline ordinal logistic regression model to determine whether the inclusion of 
BCATc, BCATm, the amino acids and brain sub-volumes would improve the 
predictive capability of the baseline model. This modelling utilising linear 
discriminant analysis and ordinal logistic regression using MoCA as a baseline 
model was repeated using Dentate Gyrus volume in replace of MoCA. We further 
sought to investigate the utility of the blood markers in isolation and repeated the 
modelling with BCATm as the baseline marker. Optimal sensitivity and specificity 
for predicting MCI or AD, and for AD was determined using the ordinal logistic 
regression model through the maximisation of Youden’s Index. 
 
3.5.22 - Cell Culture 
SH-SY5Y cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% foetal bovine serum (FBS). Cells were maintained at 
37°C in a saturated humidity atmosphere of 95% oxygen and 5% carbon dioxide. 
Cells were grown to 70-80% confluence before sub-cultured.  
 
3.5.23 - Nutrient Deprivation 
SH-SY5Y cells were maintained in nutrient deprived conditions through culture in 
EBSS for time periods of 12, 24 and 48 hours. Cells were maintained at 37°C in 
a saturated humidity atmosphere of 95% oxygen and 5% carbon dioxide. 
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3.5.24 - Leucine Deprivation 
SH-SY5Y cells were deprived of leucine over period of 12, 24 and 48 hours. 
Maintenance cell media was changed to Sigma SILAC media supplemented with 
L-arginine hydrochloride (0.4 mM) and L-lysine hydrochloride (0.8 mM). Cells 
were maintained at 37°C in a saturated humidity atmosphere of 95% oxygen and 
5% carbon dioxide.  
 
3.5.25 - Leucine Supplementation 
Leucine deprived SH-SY5Y cells were maintained in Sigma SILAC media, 
supplemented with L-arginine hydrochloride (0.4 mM) and L-lysine hydrochloride 
(0.8 mM), for 12, 24 or 48 hours before supplementation with 2 mM or 5 mM L-
leucine. Cells were subsequently extracted at 12, 24, 48 or 72 hours. Cells were 
maintained at 37°C in a saturated humidity atmosphere of 95% oxygen and 5% 
carbon dioxide.  
 
3.5.26 - Protein Estimation Using Micro-Bradford Assay 
A concentrated stock dye of Coomassie blue G was prepared by dissolving 300 
mg Coomassie blue G dye in 100 mL phosphorus acid/ethanol (2:1). For protein 
estimation this was diluted to a working due (3% stocky dye, 3.8% ethanol, 8% 
phosphoric acid) prior to experimentation. A purified bovine serum albumin (BSA) 
protein standard was prepared to a concentration of 1 µg/mL and aliquoted into 1 
mL volumes and stored at -20°C.  
 
Samples were diluted to an approximate concentration within the standard curve 
range, and 5 µL pipetted in triplicate into a 96 well plate. BSA protein standard 
was prepared to concentration between 0.2 µg/µL and 1 µg/µL and pipetted in 
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triplicate, before the addition of 200 µL of working dye to both standard and 
sample. Absorbance was measured at λ620 nm on an Odyssey 
spectrophotometer and a standard curve generated using the BSA dilution. 
 
3.5.27 - Seahorse Assay: Cell Culture 
SH-SY5Y cells were seeded in triplicate or quadruplicate at a density of 
60,000 cells per 100 µL of DMEM supplemented with 10% FBS. Cells were 
allowed to adhere at 37℃ for 2 hours and 150 µL of media added to each well 
to bring the final volume to 250 µL.  Cells were either leucine deprived 
(3.5.22), maintained in nutrient deprived conditions (3.5.21), leucine deprived 
and subsequently supplemented with leucine (3.5.23) or maintained under 
normal control conditions (3.5.20) 
3.5.28 - Seahorse Assay 
The day prior to performing the assay, the Seahorse sensor cartridge was 
hydrated with 1 mL of Seahorse XF Calibrant per well and incubated overnight 
at 37°C in a non-CO2 incubator.  
Assay medium was prepared by supplementing Seahorse XF Base Minimum 
DMEM with 1 mM pyruvate, 2 mM glutamine and 10 mM glucose and 
adjusting the pH to 7.4 with 0.1 N NaOH. The prepared media was 
subsequently sterile filtered and incubated at 37°C until used. 
Kit reagents for the Seahorse XF Cell Mito Stress Kit were prepared on the 
day of analysis with assay medium from powdered stocks of oligomycin, 
FCCP and rotenone/antimycin A to final concentrations of 100 µM, 100 µM 
and 50 µM, respectively. Stock solutions were diluted to a working 
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concentration of 1 µM in assay media and pipetted into the sensor cartridge 
injection ports.  
Prior to analysis, cells were washed twice in assay media and 500 µL of media 
subsequently added to each well. The plate was subsequently incubated at 
37°C in a non-CO2 incubator for 1 hour.  
The Seahorse sensor cartridge was loaded in the Seahorse Xfe24 analyser 
and initially calibrated. The hydrated utility cartridge was subsequently 
removed, and the incubated cell plate inserted for analysis. 
Data from the Seahorse was analysed with Agilent Seahorse Wave Software 
(Version 2.6.1) and values normalised against values obtained from Crystal 
Violet staining (3.5.28). 
 
3.5.29 - Crystal Violet Post Normalisation 
Cells were fixed in 100 µL of 4% paraformaldehyde for 20 minutes at room 
temperature. Cells were washed in 200 µL of PBS three times and stained 
with 0.2% Crystal Violet solution for 30 minutes at room temperature on a 
shaker. Crystal Violet solution was removed, and the cells washed again in 
200 µL of PBS three times. Cells were solubilised in 100 µL of SDS per well 
and incubated for 1 hour at room temperature on a shaker. The absorbance 
of the solution was read at 595 nm using a FLUOstar Omega microplate 
reader (BMG Labtech).  
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Chapter 4 – Development of an Isotope Dilution Liquid 
Chromatography Tandem Mass Spectroscopy Method 
 
4.1 – Introduction 
Amino acids are routinely analysed from whole blood by dried blood spots, serum, 
urine and CSF (French, 2017). Initial quantitative analysis was routinely carried 
out by ion exchange chromatography (IEC) coupled with optical detection 
(Sandlers, 2019). This method allowed the automated separation using a 
polystyrene resin column (Moore et al., 1958) and quantitative and qualitative 
analysis of amino acids by IEC after ninhydrin post column derivatisation (Moore 
et al., 1958). IEC is still adopted in a number of clinical settings with post-column 
derivatisation and UV detection used for sample analysis (Sandlers, 2019). 
Successive techniques have since been adopted, including reverse-phase high 
performance liquid chromatography (HPLC), gas chromatography, liquid 
chromatography mass spectroscopy (LC-MS) and gas chromatography mass 
spectroscopy for the measurement of amino acids. When compared to IEC, 
sample impurities have a greater effect on analysis of amino acids by HPLC and 
therefore sample clean up through pre-column or post-column derivatisation is 
required (Csapó et al., 2008). Furthermore, as with IEC, HPLC offers high 
sensitivity, however, the specificity of analysis is solely determined by retention 
time of the analyte which can lead to false findings as with the falsely elevated 
levels of phenylalanine due to coelution with ampicillin and amoxicillin (Sandlers, 
2019).  
 
The use of ion-exchange chromatography and high-performance liquid 
chromatography both require extended chromatography run times (Yang et al., 
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2013). The use of higher-pressure and smaller particle size allowed ultra-high-
performance liquid chromatography for increased sample throughput with 
comparable results to IEC (Narayan et al., 2011). In addition to these typical 
methods of chromatographic analysis gas chromatography can be used in place 
of IEC and presents results in agreement with IEC analysis (Zumwalt et al., 1987). 
However, as with both HPLC and IEC gas chromatography requires derivatisation 
prior to analysis.  
 
Overcoming this requirement, the combined techniques of chromatographic 
separation and mass spectroscopy methods offer both highly selective and 
sensitive analysis while negating the need for pre-column derivatisation. Liquid 
chromatography tandem mass spectroscopy (LC-MS/MS) has shown utility in 
analysing individual or small groups of amino acids and their metabolites (Walker 
and Mills, 1995) analysis of branched chain and aromatic amino acids for diabetes 
screening (Yang et al., 2013) and the analysis of underivatised amino acids for 
the diagnosis of inborn errors of amino acid metabolism (Piraud et al., 2005).  
 
I developed and validated an isotope dilution liquid chromatography tandem mass 
spectroscopy method for the analysis of serum and cellular lysate glutamic acid, 
isoleucine, leucine, phenylalanine, tyrosine and valine. The method requires 
minimal sample preparation with no requirement for sample derivatisation and 
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4.2 – Specific Aims 
 
Specific Aim 1: Develop an isotope dilution liquid chromatography tandem mass 
spectroscopy method for the analysis of glutamic acid, isoleucine, leucine, 
phenylalanine, tyrosine and valine.  
 
Specific Aim 2: Validate and optimise the isotope dilution liquid chromatography 
tandem mass spectroscopy (ID-LC-MS/MS) method for the analysis of glutamic 
acid, BCAAs and ArAAs in human serum  
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4.3 – Results 
 
4.3.1 – Identification of BCAA and AAA Precursor Ions and 
Determination of Product Ions 
To identify BCAA and AAA, deuterium labelled (Table 4.3.1) and unlabelled 
standards of glutamic acid, isoleucine, leucine, phenylalanine, tyrosine and valine 
were prepared to a concentration of 1 mM in 0.01% formic acid (Yang et al., 2013). 
Each amino acid was analysed separately by MS1 scan to determine the quasi-
molecular ion (M-H+) with scanning range of 100-300 m/z by introduction of the 
sample into an Agilent 6460 QQQ mass spectrometer via an Agilent 1260 Infinity 
series HPLC. These ions were subsequently entered into Agilent MassHunter 
Optimiser software (Ver. B.07.01 Build. 7.1.7112.0). Select ion monitoring of 
precursor ions at various at course and fine stepped fragmentor voltages were 
used to find the optimum field ionisation for each amino acid (Table 4.3.2). 
Product ions scans at multiple collision energies were used to establish product 
ions values, with subsequent multiple reaction monitoring of these ions at various 
collision energies used to determine the optimum collision energy for each ion. 
Product ions scans at the optimal fragmentor voltage and collision energy were 
used to fine tune the exact mass of each product ion.  
 
Isoleucine and leucine share the transitions of m/z 132.10 ® 69.10 and m/z 
132.10 ® 86.10 which presented the highest peak are ratios compared to other 
transitions. Deuterium labelled variants of these amino acids did not share 
transitions due to the difference in label size between isoleucine and leucine.  
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Table 4.3.1 – Composition of deuterium labelled internal standards 
Internal Standards Internal Standard Labelling 
Glutamic acid  L-Glutamic Acid (2,4,4-D3, 97-98%) 
Isoleucine  L-Isoleucine (D10, 98%) 
Leucine  L-Leucine (5,5,5-D3, 99%) 
Phenylalanine  L-Phenylalanine (Ring-D5, 98%) 
Tyrosine L-Tyrosine (Ring-D4, 98%) 
Valine L-Valine (D8, 98%) 
 
Table 4.3.2 – Precursor ions and fragmentor voltage for deuterium labelled and 
unlabelled amino acid standards 
Amino Acids Precursor Ion Fragmentor Voltage (V) 
Glutamic acid  148.10 90 
Isoleucine  132.10 90 
Leucine  132.10 90 
Phenylalanine  166.10 94 
Tyrosine 182.10 86 
Valine 118.10 90 
Deuterium Labelled Amino 
Acids 
Precursor Ion Fragmentor Voltage 
Glutamic acid  151.08 76 
Isoleucine  142.17 76 
Leucine  135.12 76 
Phenylalanine  171.12 76 
Tyrosine  186.11 76 
Valine  126.14 76 
 
  
Fred Hudd | 2020 
 65 
Table 4.3.3 Product ion transitions and required fragmentor voltage and collision 






Collision Energy (V) 
Glutamic acid  
148.10 → 56.10 90 20 
148.10 → 84.10 90 20 
Isoleucine  
132.10 → 69.10 90 20 
132.10 → 86.10 90 20 
Leucine  
132.10 → 69.10 90 20 
132.10 → 86.10 90 8 
Phenylalanine  
166.10 → 103.10 94 32 
166.10 → 120.10 94 20 
Tyrosine  
182.10 → 91.10 86 29 
182.10 → 165.10 86 5 
Valine 
118.10 → 55.10 90 24 












151.08 → 86.70 76 17 
151.08 → 133.10 76 5 
Isoleucine 
147.17 → 48.10 76 29 
147.17 → 78.20 76 21 
147.17 → 96.20 76 9 
Leucine 
135.12 → 46.10 76 25 
135.12 → 89.20 76 9 
Phenylalanine 
171.12 → 106.10 76 33 
171.12 → 125.10 76 13 
Tyrosine 
186.11 → 93.80 29 33 
186.11 → 140.10 76 9 
186.11 → 169.10 76 5 
Valine 
126.14 → 62.10 76 25 
126.14 → 80.20 76 9 
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4.3.2 – Mass Spectrometer Source Optimisation  
Flow dependent and compound dependent parameters were optimised using 
Agilent Source and iFunnel Optimisation software (Ver. B.07.01 Build. 7.1.7112.0) 
to reduce final serum sample injection volume and increase detector response. 
The baseline settings for analysis before optimisation and the chosen analytical 
settings achieved from source optimisation are presented in Table 4.3.4 – 4.3.8. 
Parameter alteration yielded spectral count increased between 24.11% and 
104.38% and absorbance reading increased between 23.22% and 154.36% for 
glutamic acid, leucine, phenylalanine, tyrosine and valine. Conversely, a 9.35% 
decrease in absorbance for unlabelled isoleucine was reported. 
 
Table 4.3.4 Baseline and source optimised flow and compound dependent parameter 
values for sample analysis  

















Baseline 3500 V 5 L/min 300°C 45 psi 500 V 11 L/min 250°C 
Source 




Values for source and compound dependant optimisation parameters for the baseline method 
used for initial standard analysis and the source optimised method used for subsequent 
calibrator and sample analysis.
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Table 4.3.5 Comparative percentage difference of spectral count for glutamic acid, isoleucine, leucine, phenylalanine, tyrosine and valine between 
baseline method and source optmised method 
  







































1023869 3272701 3077774 3683935 3085942 19477428 
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Table 4.3.6 Comparative percentage difference of spectral count for deuterium labelled glutamic acid, isoleucine, leucine, phenylalanine, tyrosine 
and valine between baseline method and source optmised method 
  











































55173 79783 260793 190465 1545389 549904 
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Table 4.3.7 Comparative percentage difference of absorbance for glutamic acid, isoleucine, leucine, phenylalanine, tyrosine and valine between 
baseline method and source optmised method  
  





































27146.91 86582.63 24633.15 190894.34 31944.78 246640.09 
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Table 4.3.8 Comparative percentage difference of absorbance for deuterium labelled glutamic acid, isoleucine, leucine, phenylalanine, tyrosine and 
valine between baseline method and source optmised method 
  









































1801.55 2705.72 6268.37 4592.60 36954.16 15762.23 
 
 









































3362.3 18186.19 493.82 1492.89 1898.72 69671.27 
 
Percentage differences were calculated using values obtained from analysis of amino acid standards using the baseline source parameter settings and the 
chosen optimised parameters summarised in Table 4.3.4. 
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4.3.3 – Published Chromatography and Developmental Method 
Chromatography Comparison 
Early multiple reaction monitoring (MRM) analysis showed that separation of 
mixed amino acid standards could not be achieved using a Waters XBridge Shield 
RP18 3.5 μm 2.1 x150 mm column, with co-elution of all amino acids occurring in 
under 0.3 minutes. All amino acids were present in a singular peak, determined 
through ion transition analysis, where retention times for each amino acid showed 
significant overlap and no distinct individual peak area. Figure 4.3.1 shows the 
reported chromatographic separation in Yang et al (2013) and the separation 
achieved through from my analysis using the same column and mobile phase.  
  





Figure 4.3.1: Comparison of Chromatographic Separation using a Waters XBridge RP18 
Column.  
(A) Chromatographic separation of Val, Ile, Leu, Tyr and Phe reported by Yang (2013) using 
a Waters XBridge Shield RP18 3.5 μm 2.1 x150 mm column, eluted using a mobile phase of 
98:2 0.01% formic acid in water and acetonitrile. Full separation was achieved in under 6 
minutes. (B) Chromatographic separation achieved during ID-LC-MS/MS method 
development, of Glu, Val, Ile, Leu, Tyr and Phe using the same column type and mobile phase. 
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MS/MS methods mostly focus on amino acid and metabolite
profiling, and often require a long LC run time.
Some commercial amino acid analysis kits based on the above
analytical principles have also been available. Among them, the
MS/MS kit intended for use in newborn screening is high-
throughput. However, this kit focuses on amino acids and
metabolites that are important for the detection of inborn
metabolic disorders and does not separate the isobaric leucine
and isoleucine which are important BCAAs potentially predictive
of diabetes risks.
In this study, we investigated the LC separation and MS/MS
detection of BCAAs and AAAs, especially that of the isobaric
leucine and isoleucine, and developed a specific and precise
method for the measurement of serum BCAAs and AAAs. The
method requires minimum sample preparation, performs with a
short run time and is suitable for screening potential diabetes risks.
Materials and Methods
Ethics Statement
This study has been reviewed and approved by the Ethics
Committee of Beijing Hospital, Ministry of Health. All studied
individuals had been made aware in writing of the intended use of
their sample and provided written consent.
Chemicals and Reagents
Standards of BCAAs [valine (Val), isoleucine (Ile) and leucine
(Leu)] and AAAs [tyrosine (Tyr) and phenylalanine (Phe)], HPLC-
grade acetonitrile and formic acid were obtained from Sigma-
Aldrich (St. Louis, MO, USA). Isotopically labeled internal
standards for each of the amino acids (Val-D8, Ile-D10, Leu-D3,
Tyr-D4 and Phe-D5), with isotopic purities of 99%, were
purchased from Cambridge Isotope Laboratories (Andover, MA,
USA).
BCAAs and AAAs Measurement by ID-LC/MS/MS
Calibrators and internal standards. A stock standard
mixture was prepared by dissolving the amino acids in 0.1% (v:v)
formic acid to a concentration of 100 mg/l for each amino acid.
Calibrators for Val (330.2, 165.1, 82.5, 41.3 and 20.6 mmol/l), Ile
(314.7, 157.4, 78.7, 39.3 and 19.7 mmol/l), Leu (296.4, 148.2,
74.1, 37.1 and 18.5 mmol/l), Tyr (218.3, 109.2, 54.6, 27.3 and
13.7 mmol/l) and Phe (240.0, 120.0, 60.0, 30.0 and 15.0 mmol/l)
were prepared by diluting the stock solution with 0.1% formic
acid. A mixed internal standard solution was made in 0.1% formic
acid to concentrations of approximately 223.6, 70.8, 134.1, 54.0
and 73.4 mmol/l for Val-D8, Ile-D10, Leu-D3, Tyr-D4 and Phe-D5,
respectively. The calibrators and the internal standard solution
were stored in 1-ml aliquots at 280uC until the time of analysis.
Sample preparation. Calibrators, the internal standard and
serum samples (if frozen) were thawed, mixed and equilibrated to
room temperature. Aliquots of 0.05 ml of calibrators or serum
samples were pipetted into 2-ml vials, followed by the addition of
0.05 ml of the internal standard solution and 0.4 ml of acetonitrile
containing 0.1% formic acid to each vial. The vials were then
vortexed and centrifuged at 3 1486g for 10 min. An aliquot of
0.05 ml of the supernatant was transferred to another vial and
evaporated under a stream of nitrogen until dry. The residue was
then reconstituted with 0.2 ml of 0.1% formic acid in water.
LC/MS/MS analysis. The LC separation was performed on
an Agilent 1200 series LC system. Aliquots of 2 ml of the prepared
samples were injected onto a Waters Shield C18 column (3.5 mm,
2.16150 mm) maintained at 20uC and eluted with a mobile phase
of 0.01% formic acid in water-acetonitrile (90:10) at a flow rate of
Figure 1. Ionization (MS 1) and fragmentation (MS 2) of each amino acid in tandem MS analysis. The data was collected as a 40 scan
MCA (2 s/scan), i.e. each spectra is an accumulative result of 40 scans. The most abundant precursor and product ions for the amino acids were
(M+H)+ and (M2COOH)+. The isobaric amino acids (e.g., Leu and Ile) have the similar and principal transition of m/z 132Rm/z 86. The transitions of
m/z 132Rm/z 43 and m/z 132Rm/z 69 were observed to be characteristic of Leu and Ile, respectively. It was also observed that the transitions were
not specific, and two minor signals of m/z 132Rm/z 69 and m/z 132Rm/z 43 occurred for Leu and Ile, respectively. Val, valine; Ile, isoleucine; Leu,
leucine; Tyr, tyrosine; Phe, phenylalanine; M, molecular weight; m/z, mass-to-charge ratio; MS, mass spectrometry.
doi:10.1371/journal.pone.0081144.g001
Figure 2. Multiple reaction monitoring (MRM) chromatograms of the five amino acids from a serum pool. The prepared sample was
eluted with a mobile phase of A) 0.01% formic acid in water: acetonitrile (90:10) or B) 0.01% formic acid in water: acetonitrile (98:2). Val, valine; Ile,
isoleucine; Leu, leucine; Tyr, tyrosine; Phe, phenylalanine.
doi:10.1371/journal.pone.0081144.g002
ID-LC/MS/MS for Serum BCAAs and AAAs
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e81144
(B) 
(A) 
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4.3.4 – Chromatographic Separation of Amino Acids 
Representative spectral count peaks for each amino acid with all amino acids 
eluted from the column in under 21 minutes (Figure 4.3.2). Glutamic acid, valine, 
isoleucine, leucine, tyrosine and phenylalanine were retained on the column for 
4.90 ± 1.02 mins, 6.06 ± 0.79 mins, 9.13 ± 1.60 mins, 9.95 ± 2.39 mins, 11.02 ± 
2.70 mins and 19.84 ± 3.07 mins, respectively. To decrease total run time the 
percentage of acetonitrile was increased from 2% to 20% at fourteen minutes to 
reduce the elution time of phenylalanine.  
 
 
Figure 4.3.2: Multiple reaction monitoring chromatogram of branched chain (Ile, Leu 
and Val), aromatic (Tyr and Phe) amino acids and glutamic acid.  
Samples were eluted from an Agilent ZORBAX Eclipse Plus C18 column (4.6 x 150 mm, 5 
µm) with a mobile phase of 0.01% formic acid in water – acetonitrile at a ratio of either 98:2 
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4.3.5 – Linearity of Amino Acids Standard Concentration 
Linear regression between peak area ratio and amino acid concentration was 
used to establish calibration functions for each amino acid (Representative curves 
Figure 4.3.3).  Table 4.3.9 summarises the regression coefficient, intercept, and 
correlation coefficient for each amino acid.  
 
Table 4.3.9 - Calibration parameters for glutamic acid, isoleucine, leucine, 






Standard Error of 
the Estimate (y) 
Correlation 
Coefficient (r 2) 
Glutamic acid 1.88 0.032 -0.01 ± 0.47 0.9994 
Isoleucine  0.95 0.111 -3.33 ± 3.94 0.9912 
Leucine  0.96 0.019 -1.26 ± 1.37 0.9989 
Phenylalanine 0.63 0.033 -3.43 ± 4.27 0.9907 
Tyrosine  0.72 0.020 -0.69 ± 0.69 0.9997 
Valine  0.12 0.001 0.48 ± 0.99 0.9969 
 
4.3.6 – Intra-Run and Inter-Run Assay Variation of Analysed Samples 
Intra-Run variation was determined through analysing four randomly selected 
serum samples from each participant group used in the biomarker study and 
analysed independently in triplicate. The CV’s for control, MCI and AD participants 
are summarised in Table 4.3.10, 4.3.11 and 4.3.12, respectively with cell lysate 
CV’s summarised in Table 4.3.13.  
  




Figure 4.3.3: Representative calibration curves for glutamate, isoleucine, leucine, 
phenylalanine, tyrosine and valine. 
Calibration functions for each amino acid were calculated using the linear regression between 
peak area ratio and amino acid concentration. All functions were calculated against a 50 µM 
deuterium labelled internal standard. 
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Table 4.3.10 Intra-run and inter-run method variation for control participant serum 
samples 
 Control Participants 
Results 
Serum Sample 1 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 13.05 21.21 40.26 15.22 20.67 65.53 
Intra-Run 
CV (%) 
3.32 0.45 0.26 6.62 0.68 0.87 
Inter-Run 
CV (%) 
2.53 0.73 0.43 9.32 0.99 1.31 
Results 
Serum Sample 2 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 14.29 13.56 24.74 9.74 11.63 45.19 
Intra-Run 
CV (%) 
2.45 6.69 0.27 3.15 0.44 0.37 
Inter-Run 
CV (%) 
2.04 6.94 0.26 2.59 0.36 0.39 
Results 
Serum Sample 3 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 8.42 7.42 13.07 6.10 11.39 25.83 
Intra-Run 
CV (%) 
1.46 3.05 0.58 2.34 0.64 0.28 
Inter-Run 
CV (%) 
0.71 1.73 0.30 1.34 0.51 0.16 
Results 
Serum Sample 4 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 8.20 10.10 19.03 8.86 10.03 30.70 
Intra-Run 
CV (%) 
2.40 1.97 1.12 5.29 0.40 0.74 
Inter-Run 
CV (%) 
1.15 1.52 0.85 4.40 0.28 0.53 
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Table 4.3.11 - Intra-run and inter-run variation for mild cognitive impairment participant 
serum samples 
 Mild Cognitive Impairment Participants 
Results 
Serum Sample 1 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 12.46 20.68 38.27 16.84 21.11 59.69 
Intra-Run 
CV (%) 
1.16 4.37 1.39 3.73 1.03 0.77 
Inter-Run 
CV (%) 
2.39 3.03 0.99 2.48 0.73 0.62 
Results 
Serum Sample 2 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 6.35 23.67 38.88 17.34 20.48 64.28 
Intra-Run 
CV (%) 
1.63 0.60 1.03 6.09 0.64 2.13 
Inter-Run 
CV (%) 
2.45 0.36 0.72 3.93 0.47 1.60 
Results 
Serum Sample 3 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 79.90 9.95 22.16 6.61 10.65 40.84 
Intra-Run 
CV (%) 
0.92 0.55 1.22 1.75 0.53 0.40 
Inter-Run 
CV (%) 
2.45 0.80 1.50 2.96 0.75 0.47 
Results 
Serum Sample 4 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 33.55 8.13 18.63 5.86 11.85 35.84 
Intra-Run 
CV (%) 
1.49 0.83 0.72 2.93 0.76 0.12 
Inter-Run 
CV (%) 
2.45 1.46 1.06 5.60 0.96 0.16 
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Table 4.3.12 Intra-run and inter-run variation for Alzheimer’s disease participant serum 
samples. 
 Alzheimer’s Disease Participants 
Results 
Serum Sample 1 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 4.44 5.11 11.75 6.17 13.23 20.53 
Intra-Run 
CV (%) 
1.32 0.15 0.51 0.43 1.00 0.72 
Inter-Run 
CV (%) 
2.45 0.28 0.94 0.59 1.08 0.72 
Results 
Serum Sample 2 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 30.12 5.43 13.41 8.41 16.03 26.98 
Intra-Run 
CV (%) 
2.59 2.13 2.12 5.84 2.31 2.24 
Inter-Run 
CV (%) 
2.45 3.82 3.41 5.93 2.05 2.24 
Results 
Serum Sample 3 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 66.15 12.71 27.62 11.38 12.78 52.37 
Intra-Run 
CV (%) 
13.46 1.89 0.23 5.37 0.73 0.61 
Inter-Run 
CV (%) 
2.45 1.45 0.18 4.03 0.82 0.61 
Results 
Serum Sample 4 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 76.43 5.44 15.26 5.90 9.53 31.83 
Intra-Run 
CV (%) 
2.15 0.91 0.39 1.55 0.44 1.69 
Inter-Run 
CV (%) 
2.45 1.63 0.55 2.24 0.66 1.69 
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Table 4.3.13 Intra-run and inter-run variation for control cell lysate samples 
 Cell Lysate 
Results 
Lysate Sample 1 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 117.09 23.15 26.50 16.43 16.86 30.96 
Intra-Run 
CV (%) 
1.14 1.51 1.44 1.26 1.96 4.91 
Inter-Run 
CV (%) 
0.98 0.91 0.98 1.80 1.79 3.24 
Results 
Lysate Sample 2 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 244.25 80.38 2.54 80.50 70.76 113.54 
Intra-Run 
CV (%) 
3.24 4.72 3.06 0.89 0.93 2.98 
Inter-Run 
CV (%) 
4.25 3.95 3.25 1.71 2.45 3.52 
Results 
Lysate Sample 3 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 33.86 20.05 1.05 14.29 13.48 23.82 
Intra-Run 
CV (%) 
2.45 1.85 1.23 2.25 1.67 0.14 
Inter-Run 
CV (%) 
2.05 1.55 2.51 2.44 2.30 1.32 
Results 
Lysate Sample 4 – Amino Acids 
Glutamic 
Acid 
Isoleucine Leucine Phenylalanine Tyrosine Valine 
Mean (µM) 124.87 20.19 21.03 14.15 14.46 21.19 
Intra-Run 
CV (%) 
2.19 1.61 1.86 2.48 2.37 1.97 
Inter-Run 
CV (%) 
2.35 1.23 1.22 2.14 1.93 1.67 
Fred Hudd | 2020 
 80 
4.3.7 – Analytical Recoveries of Amino Acid Standards, Serum and Cell 
Lysates 
Absolute recoveries were tested through spiking with a known concentration of 
each amino acid and analysed in triplicate. Table 4.3.14 summarises the average 
analysed concentration of amino acid standard, serum sample and cell lysate and 
percentage recovery. Analytical recoveries of all amino acids were close to 100% 
for both standards and serum. 
 
4.3.8 – Serum Sample Stability 
Serum amino acid stability when stored at -80°C was assessed over a three-
month and six-month period from sample collection. Total coefficients of variation 
were 2.12%, 1.54%, 1.29%, 2.01%, 1.40% and 1.42% for glutamic acid, 
isoleucine, leucine, phenylalanine, tyrosine and valine respectively. Intra-run and 
total coefficient of variation are summarised in Table 4.3.15. 
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Table 4.3.14 Analytical recoveries of the LC-MS/MS method  
Results 
Spiked Standard – Amino Acids 
Glu Ile Leu Phe Tyr Val 
Initial Concentration 
(µM) 
51.30 52.28 51.40 54.81 50.23 51.95 
Final Concentration 
(µM) 
102.61 104.56 102.80 109.62 100.47 103.89 
Spiked Standard (µM) 51.30 52.28 51.40 54.81 50.23 51.95 
Recovery % 104.31 95.30 99.05 94.02 102.77 100.11 
Results 
Spiked Serum – Amino Acids 
Glu Ile Leu Phe Tyr Val 
Initial Concentration 
(µM) 
12.02 16.91 31.77 11.90 15.04 48.93 
Concentration (µM) 62.97 65.29 81.74 63.19 66.09 105.25 
Spiked Standard (µM) 51.30 52.28 51.40 54.81 50.23 51.95 
Recovery % 98.96 94.08 98.39 94.80 101.00 103.83 
Results 
Spiked Cell Lysate – Amino Acids 
Glu Ile Leu Phe Tyr Val 
Initial Concentration 
(µM) 
135.40 44.82 50.15 32.84 30.04 29.38 
Concentration (µM) 196.9 96.12 105.68 84.41 83.48 84.41 
Spiked Standard (µM) 51.30 52.28 51.40 54.81 50.23 51.95 
Recovery % 105.33 98.77 104.17 96.37 103.77 103.16 
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Glu Ile Leu Phe Tyr Val 
Fresh Sample CV (%) 1.22 1.38 1.06 1.23 0.66 1.22 
Three Months CV (%) 2.36 1.20 2.06 2.02 0.74 1.97 
Six Months CV (%) 2.77 2.03 0.76 2.77 2.80 1.07 
Total CV (%) 2.12 1.54 1.29 2.01 1.40 1.42 
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4.4 – Discussion 
The focus of this chapter was to develop and validate an LC-MS method to 
analyse serum glutamic acid, the branched chain acids and the aromatic amino 
acids. This method will be subsequently utilise to determine the  clinical utility of 
these amino acids as early diagnostic markers of AD. Studies have shown 
alterations in free amino acids in the CSF of MCI and AD patients (Kaiser et al., 
2010)  
 
There are various analytical techniques for the analysis of serum amino acids with 
the primary classical analysis performed using IEC, which has associated long 
chromatography run times (Moore et al., 1958, Sandlers, 2019). Later 
implementation of HPLC and gas chromatography with or without downstream 
mass spectrometry has allowed for increased throughput analysis of these 
analytes. However, these methods require pre-column derivatisation of samples 
before analysis. To allow for high sample throughput, reduced sample preparation 
time and high sensitivity and specificity I chose to develop a LC-MS/MS method. 
LC-MS/MS has the lowest requirement for sample preparation, removing the 
need to derivatise amino acids before analysis. In addition, the use of deuterium 
labelled isotopes as internal standards allowed for multiple analyte screening with 
high specificity. I have developed and validated this method for serum analysis 
and have shown that it can effectively analyse the same amino acids in CSF and 
cellular lysates allowing for more diverse research applications and the study of 
model systems. 
 
Although LC-MS/MS amino acid analysis does not require derivatisation, direct 
amino acid analysis is challenging due to isobaric amino acids isoleucine, and 
Fred Hudd | 2020 
 84 
leucine sharing similar LC and MS properties (Yang et al., 2013). When 
developing this method, the aim was to establish separate and distinct retention 
times for isoleucine and leucine and the associated deuterium labelled internal 
standards, allowing for the specific detection of these amino acids and in 
accordance with previously validated methods for dried blood spot analysis 
(Dietzen et al., 2009). Retention times for isoleucine and leucine in my analysis 
were 9.13 ± 1.60 mins, 9.95 ± 2.39 mins, respectively, indicating that overlap of 
these analytes was possible. However, during analysis of both serum and cellular 
lysates distinct peaks were observed with no overlap in the calculation of peak 
area ratio. Furthermore, my analysis of these amino acids did not require any 
correction as described by Yang, thus minimising corrective errors (Yang et al., 
2013).  
 
In addition to the consideration of the chromatographic separation of leucine and 
isoleucine when optimising for product ion transitions, through the consideration 
of additional non-identical transitions. However, the peak area ratios were too low 
to be effective for the detection of either amino acid in serum due to the inherent 
background. Although for unlabelled isoleucine and leucine this was the case the 
selection of additionally product ion transitions for the alternatively labelled amino 
acids allowed for specific quantification. 
 
The extension of chromatography time to ensure this result meant that I was  
unable to replicate similar run times to those published by Yang, where complete 
elution of all amino acids, excluding glutamic acid was achieved in under six 
minutes (Yang et al., 2013). Comparison of MRM chromatograms indicate that 
the use of a 3.5 µm RP18 column allows for a shorter elution time compared to a 
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5 µm C18 column (Figure 4.3.1 and 4.3.2). The use of a 5 µm column reduced 
column flow from the initial input of 0.3 mL/min to 0.18 mL/min. During method 
development replication of the sub-six-minute elution time was trialled using the 
same Waters Shield C18 column (3.5 mm, 2.16 150 mm), however, through 
multiple trials no distinct peak separation was observed (Figure 4.3.1). Due to this 
issue an alternative reverse-phase C18 column was used, with no adverse effects 
seen from the increase in retention times or alternate column use. Furthermore, 
due to the automated nature of ID-LC-MS/MS analysis, extended run time does 
not pose an issue as manual sample loading is not required between injections.  
 
The optimisation of analysis parameters allowed for small sample volumes to be 
used with only 100 uL of serum or cellular lysate required for sample preparation 
and 10 µL for injection. From a clinical standpoint this is important as analysis can 
be achieved from either routine blood samples or without multiple collections. 
Through the validation process I have shown that the method is both precise and 
reproducible, with all amino acids except phenylalanine presenting below 5% 
intra-run and inter-run variation (Figure 4.3.10). However, all values were below 
the reported and accepted 10% coefficient of variation (Honour, 2011). This was 
also observed in the validation of cell lysate samples (Figure 4.3.11). Overall 
sample recoveries for serum were shown to be within 6% of total sample recovery. 
However, this method does present similar recoveries to (Yang et al., 2013)  
 
The use of this method as a diagnostic tool may require further consideration of 
optmisation to be effective in a clinical setting. Acetonitrile was chosen as it has 
a higher elution strength compared to alternative mobile phases like methanol 
(Lui, 2008). An increased percentage of acetonitrile reduced total run time by 
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reducing the elution time of phenylalanine and further increases could allow for 
shorter runs. This would be beneficial for clinical settings to allow for high 
throughput screening of samples. Additionally, the use of acetonitrile in both the 
mobile phase and the preparation of samples allowed for the deproteinisation 
before analysis in line with previously validated methods (Dietzen et al., 2009). 
Acetonitrile also has a low analytical background compared, making it the most 
suitable option for serum analysis where there is a possibility of high background 
noise due to contaminants. However, for this analysis there are no predicted 
substances that could interfere with the analysis of branched chain and aromatic 
amino acids (Piraud et al., 2003).  
 
In conclusion, an effective ID-LC-MS/MS for the analysis of glutamic acid and the 
branched chain and aromatic amino acids has been developed and validated for 
human serum and cellular lysate. This method will be a great tool for the analysis 
of serum amino acids and determination of amino acid profiles in models of 
neurodegenerative disease. 
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Chapter 5 – Novel Blood Biomarkers that Correlate with 
Cognitive Performance and Hippocampal Volumetry – 
Potential for Early Diagnosis of Alzheimer’s Disease Dementia 
 
This chapter covers information, results and discussion published in Novel Blood 
Biomarkers that Correlate with Cognitive Performance and Hippocampal 
Volumetry: Potential for Early Diagnosis of Alzheimer's Disease (Hudd et al., 
2019). Reprinted with authorisation of ISO Press – See Reference List 
 
5.1 – Introduction 
Current criteria recognise that the biological changes observed in AD occur over 
several decades defined by the National Institute of Neurological and 
Communicative Disorders and Stroke - Alzheimer’s disease and Related 
Disorders Association. Changes that occur as the disease progresses represents 
a challenge to develop new biomarkers to discriminate between disease stages 
and should include; (a) risk factors which present without symptomatic 
presentation, (b) prodromal AD dementia for those with symptomatic pre-
dementia AD and (c) AD or atypical forms of AD (Dubois et al., 2007).  
 
Current clinical assessment for those presenting with memory impairment include 
a series of neuropsychological assessments together with relevant imaging 
analysis such as magnetic resonance imaging to rule out alternate causes such 
as tumours (Sutphen et al., 2014, Viola et al., 2015). Using these approaches 
gives an 80% positive predictive value and a 60% negative predictive value for a 
clinical diagnosis of AD dementia. Advancement in imaging such as MRI (Willette 
et al., 2014), amyloid-PET  (Thal et al., 2014, Ito et al., 2014) and SPECT (O'Brien 
et al., 2014) allow for detection of brain atrophy, abnormalities in brain metabolism 
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and hypoperfusion, respectively. However, these analyses are expensive and not 
widely available. Furthermore, the clinical sensitivity and specificity of the 
combined neuropsychological assessments and imaging could be improved with 
the development of novel biomarkers.  
 
Biomarker candidates to support the diagnosis of AD include CSF analysis of total 
tau, phosphorylated tau and amyloid-β42 (Khan and Alkon, 2015), plasma Aβ1-42 
and the ratio of Aβ1-42/Aβ1-40 (Jack et al., 2010), plasma phospholipids (Shen et 
al., 2018), plasma proteins (Hye et al., 2014, Thambisetty et al., 2010, IJsselstijn 
et al., 2011, Schrijvers et al., 2011),  microRNA expression profiling (Tan et al., 
2014), multi-analyte platforms targeting neuroinflammatory changes (Kim et al., 
2014, Restrepo et al., 2013) and protein panels (Hye et al., 2006). In addition to 
these approaches, there is renewed interest in generating metabolic profiles that 
could be used collectively to better differentiate between MCI, AD and early 
disease stages.  
 
In particular, amino acids such as the BCAAs and AAAs are plausible for 
neurodegenerative diseases, with studies reporting changes in the amino acid 
profiles of patients with AD and PD (Li et al., 2010, Corso et al., 2017, Fonteh et 
al., 2007, Figura et al., 2018). Figura (2018) reported significant decreases in the 
concentration of alanine, arginine, threonine and phenylalanine in Parkinson’s 
disease. In addition to the BCAAs and AAAs, BCAT and its metabolite glutamate 
were hypothesised to have the potential to predict AD progression as new and 
novel biomarkers for AD. The choice of these analytes is based on the role of the 
BCAT proteins in regulating brain glutamate, through its function as a catalyst in 
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the reversible transamination of the BCAAs; leucine, isoleucine and valine to their 
respective branched chain α-keto acids and glutamate.  
 
This data shows for the first time that perturbations in BCAT and glutamate 
metabolism observed in AD brain is reflected in serum. The data presented shows 
the amino acid, glutamic acid, was found to be significantly increased in the serum 
of AD participants. Glutamic acid and BCAT also show correlation with several 
neuropsychological tests and structural MRI analysis indicating that the BCAT 
protein and glutamic acid show promise as early diagnostic biomarkers. The 
intrinsic link between BCAT and the metabolic pathways that are perturbed in AD 
give an advantage over other blood markers in that it is associated with AD 
disease progression. Moreover, the predictive power of BCAT as a blood 
biomarker of AD was assessed to determine whether it could be increased by 
combining with neuropsychology and neuroimaging scores, offering a combined 
assessment of AD pathology. 
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5.2 - Specific Aims 
Specific Aim 1 - To evaluate the serum profiles for glutamate, isoleucine, leucine, 
phenylalanine, tyrosine and valine for MCI and AD relative to control subjects. 
 
Specific Aim 2 – Investigate if the serum hBCAT profile for MCI and AD are altered 
relative to control subject. 
 
Specific Aim 3 - Compile a combined data set of neuropsychological tests results, 
genotype and magnetic resonance imaging data from control, MCI and AD 
participants. 
 
Specific Aim 4 – To determine the clinical utility of these biomarkers and 
determine their potential role as biomarkers of disease pathology together 
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5.3 – Results 
 
5.3.1 – Clinical Data and ApoE Genotyping 
Clinical data for each participant was determined at baseline and summarised in 
Table 5.3.1 with ApoE genotype for each group summarised in Figure 5.3.1. 
Significant differences between groups (Control/MCI/AD) were observed with 
respect to the age participants left school, years of education and report of head 
injury. The majority of patients (49%) presented with the ApoE 3/3 genotype, 
considered the ‘neutral’ genotype, 9% of patients were ApoE 4/4, which is linked 
to AD. The remainder of the patients were heterozygotes, with no participants 
expressing the ApoE 2/2 genotype, which shows a protective effect against AD 
but is also associated with familial type III hyperlipoproteinaemia (Wang et al, 
2015).  
 
Of participants with probable AD only one was shown to have the ApoE 4/4 
genotype, with the remaining four showing a heterozygote pattern. However, 
there were a number of participants designated as controls that did carry the ApoE 
4/4 genotype. Moreover, in some control participants, in particular those with the 
ApoE4 genotype, associated with a 40% greater risk of developing AD, levels of 
the BCAT proteins were increased indicating that these patients show common 
emerging profiles to participants with MCI or AD. The hypothesis in this instance 
is that these biomarkers may have scope as predictors for preclinical AD.  
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Table 5.3.1 – Clinical presentation and ApoE genotype of participants 
Clinical and ApoE 
Data Set 
Control n (%) MCI n (%) AD n (%) p-value 
Gender (female)  28 (56) 10 (46) 11 (69) 0.3603 
Age, median 
IQR 
70 (7.5) 74.5 (12.25) 75.5 (15) 0.0279 




15 (5) 13 (3) 12.5 (5.5) 0.0070 
Age left school, 
median IQR 
17 (2) 16 (2) 16.5 (3) 0.0308 
IQs score 
median (IQR) 
116.4 (16) 110.7 (13.1) 122.4 (17.5) 0.1093 
History of 
smoking  
24 (48) 11 (50) 9 (56.3) 0.9500 
Alcohol units per 
week, median 
(IQR) 
3.5 (9.25) 2 (11.5) 3 (8.25) 0.7389 
Family history of 
dementia (Yes) 
26 (52) 6 (28) 9 (57) 0.1414 
Loss of 
conscious (Yes) 
5 (10) 2 (9) 2 (13) 0.9400 
Head injury 
(Yes) 
7 (14) 9 (41) 3 (19) 0.0364 
Epilepsy (Yes) 1 (2) 0 (0) 1 (6.25) 0.3930 
 





Figure 5.3.1: Distribution of ApoE genotypes between control, MCI, AD and all 
participants.  
Percentage of ApoE genotypes 2/3, 2/4, 3/3 and 4/4 across control, MCI and AD participants. 
MCI participants presented the highest number of 4/4 genotypes, with the lowest percentage 
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5.3.2 – Increased BCAT Expression in Alzheimer’s Disease Reflects 
Brain Patterns 
Analysis of serum samples revealed increased BCAT proteins in patients with AD 
compared to healthy controls (p = 0.0005 and p = 0.0032, BCATc (Figure 5.3.2 
A) and BCATm (Figure 5.3.2 B) respectively) with clear distinction between 
groups (Table 5.3.2). Data shows that in some MCI cases their blood profiles 
reflected changes similar to the profiles of AD participants (Figure 1A, Lane 1 (AD) 
and Lane 3 (MCI) respectively). Other MCI cases did not reflect this and shared 
typical biochemical characteristics like those of control participants (Figure 1A, 
Lane 4, 5 (MCI) relative to control lanes). Table 5.3.2 summarises means scores 
of BCAT by participant group and details the results from a one-way analysis of 
variance and a post-hoc application of Tukey’s honestly significant differences 
test for each measure. Mean levels for BCATc and BCATm significantly differ 
between at least two patient groups (p < 0.05). In the sample, there is a significant 
difference in the level of the BCAT proteins between control and MCI (p = 0.0235 
and p = 0.0084, for BCATc and BCATm, respectively) and control and ADD (p 
=0.0013 and p = 0.0474, BCATc and BCATm, respectively). 
 
5.3.3 – Increased Levels of Glutamate in AD Serum Differentiate Between 
Groups 
Serum amino acids, in particular the BCAAs, glutamate and AAAs showed an 
altered amino acid profile from AD participants relative to controls. In particular, 
there was an increase in the concentration of glutamate from control to MCI to 
ADD (Table 5.3.3). Table 5.3.3 summarises mean levels and within group 
variation for the amino acid levels. In the sample, mean levels of isoleucine, 
leucine, valine and tyrosine significantly differ between conditions. In this sample, 
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significant differences in mean levels of isoleucine, leucine, tyrosine and valine 
between conditions were observed. A pairwise comparison between control and 
MCI participants showed significant differences in isoleucine (p = 0.0077), leucine 
(p = 0.0141) and valine (p = 0.0063), indicating that the profile of these amino 
acids may be early predictors of preclinical AD (Figure 5.3.2). 
 
5.3.4 – Differentiation Between Participant Groups 
The hippocampus of AD participants displays marked atrophy compared to 
control (Figure 5.3.4). MRI data indicates an evident reduction of total 
hippocampal volume in both MCI and mild AD, with primary reduction observed 
in the CA1, dentate gyrus and subiculum, however tissue loss is uneven in these 
sub-regions. To gain understanding of the functional consequences of the 
described morphometric changes in the hippocampus and sub-regions versatile 
cognitive neuropsychology tests were administered to the same participant group 
(Table 5.3.4). The Montreal Cognitive Assessment test, Paired Associative 
Learning (PAL) and Hopkin’s Verbal Learning Test Revised (HVLT) verbal 
learning test all discriminate between AD, MCI and healthy older groups. Table 
5.3.4 summarises mean scores on cognitive assessments by patient group and 
the results from a one-way analysis of variance and a post hoc application of 
Tukey’s honestly significant differences test for each measure. In each instance, 
sample means levels demonstrate significantly poorer cognitive ability in MCI 
compared to control, and significantly poorer cognitive ability in AD compared to 
MCI. The F-statistic indicates MoCA scores have the greatest within sample 
discriminatory effects. Mean levels for CA1 Volume, Dentate Gyrus, Subiculum, 
Hippocampal, and Entorhinal monotonically decrease with progression from 
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Control, to MCI, to AD, and these trends are statistically significant effects (Table 
5.3.5). 















Figure 5.3.2 Western blot analysis of BCAT in serum from control, MCI and AD participants.  
The protein concentration of serum samples was calculated using the Schaffner and Weissmann method (Schaffner W, 1973) and separated on a NuPAGE® 
Novex® 4-12% Bis-Tris followed by Western blot analysis using antibodies specific for BCATc and BCATm (1/1000 dilution). Positive bands were visualised 
using chemiluminescent HRP substrate and an Odyssey® Fc Imaging System (LI-COR Biosciences). Integrated area densitometry was carried out using Image 
Studio Ver 5.2 and the results were measured in relation the total protein. Panel A: Sample western blot analysis with box plot of BCATc from control, MCI and 
AD participants. Panel B: Sample western blot analysis with box plot of BCATm from control, MCI and AD. (N=75). 
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Table 5.3.2 – BCATc and BCATm (mean ± standard deviation) summarised by participant group 
BCAT 
Control 
 (n = 45) 
MCI                
(n = 16) 
AD  
(n = 12) 
ANOVA  
F (2, 7) 
p-value  
Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
BCATc   98.21 ± 113.8 366.2 ± 622 505.4 ± 402.3 8.524 0.0005 0.0235 0.0013 0.5368 
BCATm  123.5 ± 123.4 441.1 ± 654.8 402.4 ± 396.4 6.239 0.0032 0.0084 0.0474 0.9562 
 
 
Table 5.3.3 – Amino acid levels (µmol/L) in the serum of control, MCI and AD participants  
Amino Acid  
Control  
(n = 42) 
MCI  
(n = 17) 
AD  
(n = 11) 
ANOVA 
F (2, 67) 
p-value 
Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
Glutamate   0.8436 ± 0.5192 1.791 ± 1.308 2.370 ± 2.054 10.570 0.0001 0.0103 0.0003 0.3649 
Isoleucine  0.6056 ± 0.2861 0.993 ± 0.573 0.734 ± 0.634 4.837 0.0109 0.0077 0.6554 0.2792 
Leucine  1.1650 ± 0.5998 1.874 ± 0.978 1.631 ± 1.369 4.620 0.0132 0.0141 0.2476 0.7420 
Phenylalanine  0.5356 ± 0.2926 0.773 ± 0.416 0.599 ± 0.435 2.814 0.0670 0.0530 0.8535 0.4044 
Tyrosine 0.6735 ± 0.3320 1.031 ± 0.468 1.112 ± 1.065 4.477 0.0150 0.0607 0.0490 0.9209 
Valine 2.0280 ± 1.0340 3.323 ± 1.824 2.763 ± 1.940 5.347 0.0070 0.0063 0.2833 0.5669 
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Figure 5.3.3 - Amino acid profiles of control, MCI and AD participants. 
Panel A: Box plot showing serum glutamate concentration for control (n = 42; median 0.6667, 
range 0.07649 – 2.171), MCI (n = 17; median 0.9547, range 0.2818 – 4.341) and AD 
participants (n = 11; median 2.212, range 0.2203 – 7.211). Panel B: Box plot showing serum 
isoleucine concentration for control (n = 42; median 0.6291, range 0.08 – 1.728), MCI (n = 17; 
median 0.9008, range 0.387 – 2.651) and AD participants (n = 11; median 0.5541, range 
0.242 – 2.508). Panel C: Box plot showing serum leucine concentration for control (n = 42; 
median 1.174, range 0.1649 – 3.762), MCI (n = 17; median 1.703, range 0.8577 – 4.769) and 
AD participants (n = 11; median, range 0.5615 – 5.429). Panel D: Box plot showing serum 
phenylalanine concentration for control (n = 42; median 0.5552, range 0.03266 – 1.386), MCI 
(n = 17; median 0.6218, range 0.2508 – 1.905) and AD participants (n = 11; median 0.4479, 
range 0.2827 – 1.828). Panel E: Box plot showing serum tyrosine concentration for control (n 
= 42; median 0.6735, range 0.09193 – 1.67), MCI (n = 17; median 1.009, range 0.4194– 
2.515) and AD participants (n = 11; median 0.8049, range 0.4791 – 4.242). Panel F: Box plot 
showing serum valine concentration for control (n = 42; median 2.019, range 0.3036 – 6.422), 
MCI (n = 17; median 2.901, range 1.473 – 9.005) and AD participants (n = 11; median 1.928, 
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In all cases for CA1 Total, CA2 Total, Dentate Gyrus, Subiculum and 
Hippocampal the mean levels in Control are significantly higher than MCI, and AD 
(p < 0.05), but with no significant difference between MCI and AD (p > 0.05). The 
dentate gyrus subfield showed the strongest effect within the sample. 
 
BCATm and BCATc are both significantly correlated (r = 0.753, p < 0.0001) and 
are also significantly correlated with MoCA score (r = -0.240, p = 0.038 BCATm 
and r = -0.329, p = 0.004 BCATc). Glutamic acid levels did not significantly 
correlate with BCATm (r = -0.140, p = 0.267) or BCATc (r = 0.150, p = 0,235). 
However, glutamic acid was significantly correlated with MoCA score (r = -0.329, 
p = 0.006). Conversely, leucine, isoleucine, phenylalanine, tyrosine and valine are 
not correlated with MoCA score (p > 0.2 in all cases). These amino acids do form 
a mutually correlated system (r > 0.85, p < 0.0001) and leucine, isoleucine and 
valine are each significantly correlated with both BCATm and BCATc. CA1, CA2, 
dentate gyrus, hippocampal and entorhinal volumes are all significantly correlated 
with MoCA score (r > 0.400, p < 0.01) as shown in Table 5.3.6. 
 
Multivariate discriminant analysis shows that MoCa scores alone have good and 
significant discriminant powers between control, MCI and AD groups 
(classification accuracy 81.8%; leave one-out cross validated 81.8%). This 
baseline discriminant model is significantly improved with the inclusion of any one 
of BCATc, BCATm, glutamic acid, isoleucine, leucine, phenylalanine, tyrosine or 
valine (shown in Table 5.3.7). Likewise,ordinal logistic regression shows that 
MoCA scores by themselves have good predictive powers for Control/MCI/ADD 
(Figure 5.3.5). However, this baseline discriminant model is not improved with the 
inclusion of any of the brain volume measures. MoCA scores alone are also 
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shown to have good predictive powers for control/MCI/AD from 15 ordinal linear 
regression. This baseline ordinal logistic regression model is significantly 
improved by the inclusion of any of, BCATm (p = 0.007), glutamic acid (p = 0.035), 
Leucine (p = 0.019), Valine (p = 0.008), Phenylalanine (p = 0.030), or Tyrosine (p 
= 0.005). Yet, this baseline inclusion of BCATc (p = 0.317), nor by the inclusion 
of the brain volume measures.  
 
Multivariate discriminant analysis shows that Dentate Gyrus sub-volume was 
shown to have some significant discriminant powers between Control/MCI/AD 
(classification accuracy 61.6%; leave one-out-cross validated 61.6%). This 
baseline discriminant model is significantly improved with the inclusion of any one 
of BCATm, glutamic acid, leucine. Likewise, ordinal logistic regression shows that 
Dentate Gyrus volume is significantly related to outcome. Further, this baseline 
ordinal logistic regression model is significantly improved by the inclusion of any 
of, BCATm (p = 0.011), glutamic acid (p = 0.003), leucine (p = 0.045), valine (p = 
0.048) but with levels of predictive accuracy notably lower when compared with 
the models using MoCA.  
 
For blood markers only, BCATm and glutamic acid in combination and individually 
show good discriminatory powers (Table 5.3.7). For MoCA alone, sensitivity and 
specificity were 0.819 and 0.937 with respect to ADD. This estimate was 
significantly improved when combined with BCATm or the amino acids (Table 
5.3.7). Of note is the measure of BCATm with MoCA which improved sensitivity 
to 0.903 but specificity to 1.00 indicating that this protein together with the MoCA 
measurement correctly categorised all participants that did not show evidence of 
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AD pathology into the correct group. In contrast, the MoCA models were not 
greatly improved by the inclusion of the Dentate Gyrus subfield volume.
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(n = 50) 
MCI  
(n = 22) 
AD  
(n = 16) 
ANOVA 
F (2, 85) 
p-value 
Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
MoCA   27.26 ± 1.780 22.27 ± 2.84 16.44 ± 5.04 90.77 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 Control  
(n = 47) 
MCI  
(n = 19) 
AD  
(n = 12) 
ANOVA 
F (2, 75) 
p-value 
Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
PAL Mean 
Reaction Time 
2148 ± 454.1 3264 ± 1267 5774 ± 3341 29.73 < 0.0001 0.0176 < 0.0001 < 0.0001 
PAL Total Acc 0.695 ± 0.115 0.542 ± 0.108 0.349 ± 0.102 49.80 < 0.0001 < 0.0001 < 0.0001 < 0.0001 
 Control 
(n = 50) 
MCI 
(n = 22) 
AD 
(n = 14) 
ANOVA 
F (2, 83) 
p-value 
Pairwise Comparison 
 Control vs MCI Control vs AD MCI vs AD 
HVLT 20 
Minute Delay 
9.26 ± 2.489 4.364 ± 3.170 1.000 ± 1.414 69.27 <0.0001 < 0.0001 < 0.0001 0.0007 
 Control 
(n = 41) 
MCI 
(n = 17) 
AD 
(n = 6) 
ANOVA 
F (2, 61) 
p-value 
Pairwise Comparison 
 Control vs MCI Control vs AD MCI vs AD 
HVLT 24 Hour 
Delay 
8.976 ± 2.779 3.529 ± 3.204 0 ± 0 42.06 < 0.0001 < 0.0001 < 0.0001 0.0260 
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Table 5.3.5 – Subfield volumes for AD, MCI and control participants 
Subfield  
Control  
(n = 44) 
MCI  
(n = 18) 
AD  
(n = 11) 
ANOVA 
F (2, 70) 
p-value 
Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
CA1 1.713 ± 0.2401 1.410 ± 0.3711 1.370 ± 0.4200 9.486 0.0002 0.0021 0.0040 0.9367 
CA2 0.020 ± 0.0051 0.016 ± 0.0050 0.015 ± 0.0050 5.578 0.0057 0.0228 0.0343 0.9621 
CA3 0.076 ± 0.0160 0.081 ± 0.0150 0.082 ± 0.0310 0.670 0.5146 0.6734 0.5992 0.9709 
Dentate Gyrus 1.087 ± 0.1186 0.955 ± 0.1830 0.886 ± 0.1890 10.62 < 0.0001 0.0063 0.0004 0.4493 
Subiculum  0.483 ± 0.0631 0.425 ± 0.1060 0.389 ± 0.0718 8.353 0.0006 0.0242 0.0015 0.4344 
Hippocampal 3.623 ± 0.3848 3.141 ± 0.6780 3.019 ± 0.7129 9.015 0.0003 0.0046 0.0031 0.8158 
Entorhinal 0.579 ± 0.0878 0.529 ± 0.1210 0.433 ± 0.1288 9.084 0.0003 0.1941 0.0002 0.0477 
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Table 5.3.6 – Correlation analysis with MoCA 
Clinical and ApoE Data Set r-value p-value Measure r-value  p-value 
CA1 0.458 < 0.0001 Glutamic Acid -0.317 0.007 
CA2 0.408 0.0001 Isoleucine -0.056 0.643 
CA3 -0.340 0.0788 Leucine 0.078 0.524 
Dentate Gyrus 0.456 < 0.0001 Phenylalanine 0.083 0.492 
Subiculum  0.463 < 0.0001 Tyrosine  -0.109 0.368 
Hippocampal 0.450 < 0.0001 Valine  -0.017 0.887 
Entorhinal 0.496 < 0.0001 
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Table 5.3.7 - Percentage accuracy under leave one-out-out (L-O-O) cross-validation of baseline linear discriminant model (A) (MoCA (B) or Dentate 
Gyrus (C)) and extended model, along with p-value for inclusion of additional parameter in the baseline ordinal regression model. Optimal sensitivity 
and specificity for MCI and AD combined, and AD only using the ordinal logistic regression model. 
 
A 
Discriminant Analysis Logistic Regression MCI or AD AD 
Accuracy L-O-O Accuracy p-value Sensitivity and Specificity Sensitivity and Specificity 
BCATm 62.7 62.7 N/A 0.744; 0.704 0.836; 0.727 
BCATm + BCATc 64.0 64.0 0.774 0.756; 0.767 0.710; 0.923 
BCATm + Glu 63.6 60.6 0.003 0.704; 0.872 0.800; 0.818 
BCATm + Ile 68.2 63.6 0.525 0.744; 0.741 0.818; 0.727 
BCATm + Leu 62.1 62.1 0.186 0.744; 0.704 0.782; 0.727 
BCATm + Phe 62.1 60.6 0.646 0.718; 0.741 0.800; 0.727 
BCATm + Tyr 62.1 59.1 0.064 0.744; 0.704 0.836; 0.727 
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B 
Discriminant Analysis Logistic Regression MCI or AD AD 
Accuracy L-O-O Accuracy p-value Sensitivity and Specificity Sensitivity and Specificity 
MoCA 81.8 81.8 N/A 0.900; 0.895 0.819; 0.937 
MoCA + Dentate Gyrus 81.8 81.8 0.293 0.909; 0.931 0.903; 0.909 
MoCA + BCATc 83.0 83.0 0.317 0.978; 0.933 0.850; 0.923 
MoCA + BCATm 86.7 84.0 0.007 0.978; 0.967 0.903; 1.000 
MoCA + Glu 88.4 85.5 0.035 0.929; 0.967 0.879; 0.909 
MoCA + Ile 87.0 85.5 0.044 0.976; 0.967 0.828; 0.909 
MoCA + Leu 89.9 84.1 0.019 0.976; 0.967 0.828; 0.909 
MoCA + Phe 88.4 85.5 0.030 0.929; 0.967 0.845; 0.909 
MoCA + Tyr 87.0 85.5 0.005 0.952; 0.967 0.845; 1.000 
MoCA + Val 87.0 84.1 0.008 0.976; 0.967 0.828; 0.909 
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C 
Discriminant Analysis Logistic Regression MCI or AD AD 
Accuracy L-O-O Accuracy p-value Sensitivity and Specificity Sensitivity and Specificity 
Dentate Gyrus 61.6 61.6 N/A 0.682; 0.655 0.806; 0.727 
Dentate Gyrus + MoCA 81.8 81.8 < 0.001 0.955; 0.897 0.903; 0.901 
Dentate Gyrus + BCATc 63.0 63.0 0.127 0.769; 0.792 0.811; 0.800 
Dentate Gyrus + BCATm 65.1 62.9 0.011 0.897; 0.708 0.887; 0.800 
Dentate Gyrus + Glu 73.8 68.9 0.003 0.769; 0.818 0.923; 0.778 
Dentate Gyrus + Ile 63.0 63.0 0.095 0.897; 0.727 0.769; 0.778 
Dentate Gyrus + Leu 63.0 63.0 0.045 0.846; 0.818 0.731; 0.778 
Dentate Gyrus + Phe 63.0 63.0 0.187 0.718; 0.818 0.788; 0.778 
Dentate Gyrus + Tyr 63.0 63.0 0.087 0.897; 0.773 0.827; 0.778 
Dentate Gyrus + Val 67.2 67.2 0.048 0.897; 0.673 0.846; 0.677 
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Figure 5.3.4 - T2-weighted coronal MRI images of healthy elderly control (left) and ADD 
patient (right).  
The Hippocampus of ADD patient displays marked atrophy compared to control. Left 
Hippocampus and surrounding cortices is masked for each subject using ASHS protocol: 
Red=CA1; Purple=DG; Yellow=CA3; Lime Green=CA2; Pink=Subiculum; Pale 
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5.5 – Discussion 
There is a wide range of application cations for biomarkers in clinical research, 
drug discovery and clinical diagnosis. Validation of new and novel fluid biomarkers 
for dementia open possibilities for alternative or supportive diagnostic makers that 
through combination with other assessment modalities could hugely increase 
prediction values. This data suggest that the predictive power of BCAT or glutamic 
acid (glutamate) is increased by either structural information from MRI of 
vulnerable brain structures (Willette et al., 2014) and/or neuropsychological tests 
(Dubois et al., 2007). Through this three-discipline study we have begun to 
address the issue of early AD diagnosis, with data that shows the potential of 
BCAT and glutamic acid (glutamate) to predict AD. 
 
Current guidelines address the disease on a spectrum with three specific stages; 
an early, preclinical stage presenting no symptoms, a middle stage of MCI and a 
final stage marked by symptoms of dementia (Dubois et al., 2007). Formal 
acknowledgement in diagnostic criteria for the use of biomarkers as possible 
indicators of underlying AD pathology has been made (Dubois et al., 2007),  
however, it is recommended that the use of biomarkers in this field are research 
focused rather than applied in a clinical setting. Previous studies by our group 
have shown that the levels of the BCAT proteins are increased in the 
hippocampus; frontal and temporal cortex in AD relative to matched control 
brains, with BCATm upregulation correlating with Braak stage, suggesting that 
the level of this enzyme is related to disease progression (Hull et al., 2015, Hull 
et al., 2012). The data has shown increased levels of serum BCAT proteins in 
participants with AD compared to healthy controls with clear distinction between 
groups (Figure 5.4.2 and Table 5.4.2).  No significant difference between mean 
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BCAT levels in MCI compared to the more severe AD participants were observed. 
This argues that BCAT may reflect early pathological changes in the brain 
supporting the findings in brain tissue. Furthermore, the correlation of serum 
BCAT with MoCA score, various neuropsychological tests and several indicators 
of hippocampal volume reduction, suggest that BCAT is a valid measure of AD 
pathogenesis (Figure 5.3.5 and Table 5.3.6). 
 
Additional studies using cell and animal models suggest that increased levels of 
BCATs may be initially be neuroprotective (Hull et al., 2015), however, sustained 
increased BCAT expression could increase the production of glutamate and 
exacerbate neuronal excitotoxicity, potentially contributing to cell death. From the 
analysis of serum glutamate, the data shows a significant increase in the levels 
of serum glutamic acid that monotonically increased across the three groups 
(Figure 5.3.2 A). Interestingly, proton magnetic resonance (1H MRS) assessment 
of metabolites such as glutamate showed a decrease in hippocampal brain 
glutamate between control, MCI and AD participants (Rupsingh et al., 2011). In 
AD, hippocampal, frontal, temporal and parietal cortex glutamatergic neurons are 
reported to be severely affected relative to similar neurons in the motor and 
sensory cortex and considered a possible early event in the pathogenesis of the 
disease (Francis, 2003, Revett et al., 2013). A recent study has indicated that 
measures of the glutamatergic system correlated with MCI more so than Aβ or 
Tau and that there is an increase in glutamatergic synapses in individuals with 
MCI, supporting the theory that an increased activity of BCAT may be initially 
neuroprotective (Bell et al., 2007). Several aspects of the glutamate/glutamine 
cycle are perturbed in AD brain including (a) reduced levels of VGLUT1 and 2 in 
the prefrontal cortex of individuals with AD (Kashani et al., 2008) (b) Aβ peptides 
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accumulate more in VGLUT1/2-containing terminals than in non-VGLUT 
terminals indicating a preferential targeting of these type of neurons (Sokolow et 
al., 2012) (c) synaptic glutamate transporter defect, an early sign in disease 
pathology (Cummings et al., 2015), (d) low levels of glutamate synthetase in 
astrocytes (Yeh et al., 2013, Olabarria et al., 2011). This extensive evidence 
together with this data supports a role for BCAT and glutamate as early indicators 
of disease pathology. 
 
Links have been shown between the levels of dietary amino BCAAs and reduced 
cognitive function, however, the mechanism by which conditions manifest is not 
entirely understood thus requiring further investigation. In the field of BCAA 
analysis there are several studies which present mixed data sets with wide 
variability, which is possibly linked to either study design, method or the 
instrumentation used  (Griffin and Bradshaw, 2017). Study of the BCAAs show 
that levels of leucine, isoleucine and valine independently and together are lower 
in control relative to MCI and AD participants. Pairwise comparisons show there 
is a significant increase in the BCAAs in MCI relative to control, where monitoring 
a change over time holds promise as a predictor of AD. Genetic variants have 
been identified through genome-wide association study (GWAS) that carry an 
association with increased BCAA levels (Lotta et al., 2016), with an additional 
study suggesting that those with a genetic predisposition to raised plasma 
isoleucine were positively associated with AD (Larsson and Markus, 2017). 
Furthermore, recent investigations have shown the predictive value of BCAAs for 
the development of new-onset diabetes up to 12 years after the baseline 
examination, which incidentally has a 50% increased risk of developing AD 
(McCormack et al., 2013, Newgard et al., 2009). Conversely, BCAA levels have 
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be shown to be low in other conditions such as liver disease (Itou et al., 2009) 
and traumatic brain injury (TBI) (Vuille-Dit-Bille et al., 2012, Jeter et al., 2013). In 
TBI, decreases in brain glutamate and the plasma concentrations of the BCAAs 
are observed, whereas the concentrations of phenylalanine, tryptophan and 
tyrosine are increased and are associated with significant intracranial pressure 
and jugular venous oxygen saturation changes (Vuille-Dit-Bille et al., 2012). 
Significant decreases in plasma BCAAs are also observed in Huntington’s 
disease, which correlate with the severity of the disease over time (Mochel et al., 
2011, Mochel et al., 2007). These clinical presentations highlight how sub-optimal 
or chronically high levels of BCAAs affect brain function and how the BCAT 
metabolic proteins and activity are important to cognitive wellbeing. Further study 
is required to better determine the optimal levels of BCAAs and BCAT required 
for optimal cognitive well-being, which in turn will help to better inform clinical 
practice. 
 
In 2015 a report presented data on a patient presenting with hypervalinaemia, 
hyperleucine-isoleucinemia, headaches, and MCI with brain white matter lesions 
(Wang et al., 2015). Traditional clinical diagnosis of these presentations would be 
related to the autosomal recessive disorder Maple Syrup Urine disease, which is 
caused by a BCKDC deficiency (Chuang and Chuang, 2000). Two heterogeneous 
BCAT2 mutations, including c.509G-A and c.790G-A, were found, indicating that 
when BCAT2 is mutated, BCAA metabolism is perturbed, resulting in brain lesions 
and cognitive impairment. Treatment with Vitamin B6 caused the symptoms to 
subside and the lesions to decrease, with longer term vitamin B supplementation 
over a period of 2 years was shown to slow accelerated brain atrophy in elderly 
with MCI by 30%, (Smith et al., 2010).  
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We propose that BCAT is upregulated in a neuro-protective manner which 
responds to either nutritional or redox changes in the cell. However, as with most 
biological systems an imbalance in metabolism could generate secondary 
consequences, such as increased glutamate production leading to neuronal 
toxicity, or if oxidised could assume a moonlighting neurotoxic role (Conway and 
Lee, 2015). Together both the BCAT proteins and their metabolites hold promise 
as markers of AD pathology but also as targets for future therapy-related 
approaches. 
 
In this study we took a combined approach, utilising serum analyses, advanced 
MRI imaging and neuropsychology tests to detect alterations in the hippocampus 
in MCI and AD participants. MRI data indicated a reduction of total hippocampal 
volume primarily in the CA1 region, dentate gyrus and subiculum and is evident 
in both MCI and AD brains. Administration of versatile cognitive neuropsychology 
tests to the same participants allowed us to gain understanding of functional 
consequences of morphometric changes in the hippocampus and its sub-regions. 
Here, morphological changes detected by MRI analysis correlated with MoCA 
(Table 5.3.6) indicating that these 2 measures can be used in assessment of 
control compared with AD participants. Using the percentage accuracy under 
leave one-out-out cross validation of baseline linear discriminant model (MoCA or 
Dentate Gyrus) showed that a combination of measuring the BCAT proteins and 
the amino acids with MoCA or the dentate gyrus increased the sensitivity and 
specificity of these tests in discerning between MCI and AD. Diagnostically the 
most clinically relevant assays to date include measurement of CSF Aβ1-42, total 
tau, phosphorylated tau and the Aβ/total tau index (ATI). Using combinations of 
these biomarkers the clinical sensitivity and specificity can vary between studies 
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but can reach values up to 90% and 85%, respectively (Lewczuk et al., 2018). 
However, current studies measuring these parameters in blood have not 
generated substantial data in support of their use diagnostically. Other studies 
favour multi-analyte approaches such as the Luminex-based platform that 
identified 30 protein markers in discriminating AD from controls (AUC=0.95) 
indicating that a panel approach has potential to better delineate between 
participant groups. 
 
In conclusion, using this proof of concept model the measurement of BCATm and 
the amino acids has showed an increase in the sensitivity and specificity of MoCA 
analysis in correctly identifying participants free of AD pathology (100%) but also 
those with the disease to 90% accuracy. This analysis shows that there is a high 
degree of information overlap between MoCA, the MRI measures, and the amino 
acids. However, both BCATm and glutamate, significantly improve the predictive 
potential of MoCA, and significantly improve the predictive potential of the MRI 
measures. These findings, coupled with the underpinning of extant literature, 
indicate that the combined modalities show diagnostic subject to the caveats of 
single centre cross-sectional exploratory studies. 
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Chapter 6 – The Effect of Leucine Deprivation on Cellular 
Metabolism 
 
6.1 - Introduction 
The essential dietary amino acid leucine is important for protein synthesis and 
maintenance of metabolic function alongside isoleucine and valine. As previously 
discussed, these amino acids are the key nitrogen donors for the synthesis of 
glutamate in the brain (LaNoue et al., 2001) and are fundamental in maintaining 
CNS neurotransmitter homeostasis where alterations can cause neurologic 
dysfunction (Yudkoff, 1997). Within this, the balance of intra-neuronal and 
extracellular glutamate is important to allow for normal release upon 
depolarisation and avoid excessive build up and possible excitotoxicity 
respectively (Yudkoff, 1997). In AD it is hypothesised that chronic glutamate 
excitotoxicity leads to neuronal death and symptomatic cognitive decline 
(Lewerenz and Maher, 2015), however the exact mechanisms are yet to be 
determined. Increased understanding of the effect of altered leucine levels in the 
brain may shed light on the mechanisms by which these altered neurotransmitter 
profiles occur. 
 
In addition to increasing our understanding of the role of leucine as a precursor to 
neurotransmitter synthesis, further understanding of its role as an activator of 
mTOR (Jewell et al., 2013) and the relation to autophagy pathway would help to 
determine some of the mechanistic underpinning of neurodegenerative disease 
development and progression. Under normal physiological conditions the mTOR 
pathway is responsible for neural development and circuit formation (Lipton and 
Sahin, 2014), and the regulation of autophagy (Jung et al., 2010). mTOR acts as 
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a sensor of cellular nutritional status whereby reduction in cellular growth factors 
or conditions of nutrient starvation results in the inhibition of mTOR, leading to 
autophagy (Jung et al., 2010). In AD there is a strong implication that dysregulated 
autophagy has a role on the disease pathogenesis (Saxton and Sabatini, 2017), 
with reports of early disease state alteration of mTOR1 activity and lysosomal 
dysfunction (Uddin et al., 2019), which could subsequently lead to increased 
accumulation of aggregates (Perez et al., 2015). However, there is still uncertainty 
in this field as to whether increased mTOR activation or reduced levels of BCAAs 
are beneficial in disease state. 
 
In contrast to reports of reduced BCAA being beneficial, a review of studies into 
BCAA supplementation showed that there is a therapeutic benefit in the 
supplementation of BCAAs in cases of severe TBI (Sharma et al., 2018), whereby 
improved cognition was noted after treatment. Although these accounts appear 
to be conflicting it is more likely due to the fact that it is the balance of BCAAs is 
important i.e. excess or limiting is toxic. Therefore, a greater understanding of 
these pathways will be an important avenue for identification of new and novel 
therapeutic targets.  
 
This work has shown that in leucine deprived conditions intracellular glutamic acid 
is decreased significantly compared to controls. Interestingly, the level of BCATc 
was shown to be significantly increase in response to LD conditions which 
correlated with an increase in autophagy markers Beclin 1 and LC3 are shown to 
be significantly increased. This finding may indicate a possible interaction of 
hBCAT with the autophagy pathway. Finally, this work has shown significant 
metabolic perturbation in conditions of acute leucine deprivation when compared 
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to controls and in line with complete nutrient deprivation of cellular models. 
Overall, these findings indicate that leucine deprivation has a widespread effect 
on intracellular mechanisms in neuronal cells, which may have possible influence 
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6.2 – Specific Aims 
 
Specific Aim 1 – To evaluate the glutamic acid, BCAA and AAA profiles in cellular 
model SH-SY5Y under leucine deprived and nutrient deprived conditions in 
addition to the response to leucine supplementation 
 
Specific Aim 2 – Analyse key markers of autophagy, Beclin 1, LC3, mTOR and 
Phospho mTOR to determine the effect of leucine deprivation and the possible 
role or interaction of BCAT with the autophagy pathway 
 
Specific Aim 3 – Determine the metabolic profile of SH-SY5Y cells under leucine 
deprived and nutrient deprived conditions  
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6.3 – Results 
 
6.3.1 – Perturbations in the Levels of Glutamic Acid, BCAAs and AAAs 
in Leucine and Nutrient Deprived Conditions 
 
Glutamic acid, isoleucine, leucine, phenylalanine, tyrosine and valine levels in the 
cellular lysate of SH-SY5Y cells was determined by ID-LC-MS/MS after treatment 
under leucine deprived, nutrient deprived conditions for 12, 24, 48 and 72 hours. 
In response to leucine deprivation for 24 hr there was a significant decrease in 
the concentration of glutamate relative to control (p value = <0.0001) with 
concentrations lower than nutrient deprivation reported, indicating that leucine is 
fundamentally important to glutamate regulation. Of the amino acids measured 
glutamate alone was shown to significantly decrease under control, leucine 
deprived and nutrient deprived conditions over a 72 hour period (Figure 6.3.1).  
Furthermore, there was a significant increase in all other amino acids except 
leucine observed at 12 hours (Summarised in Table 6.3.1) relative to control or 
nutrient deprived conditions suggesting that these other amino acids are taken up 
in the absence of leucine. However, over time the concentration of these amino 
acids also significantly decreased relative to control conditions (Tables 6.3.2-
6.3.5). 
 
6.3.1 – The Effect of Leucine and Nutrient Deprivation on Autophagy and 
the Expression of hBCATc 
 
Under conditions described above the expression profiles of Beclin 1, LC3I/II, 
mTOR, and hBCATc were assessed by Western blot analysis in cellular lysates 
of SH-SY5Y cells. All measurements were normalised against the loading control 
a-tubulin and statistically analysed using an unpaired t-test. 
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Figure 6.3.1 – Box and whisker plots of cellular lysate Glu, Ile, Leu, Phe, Tyr and Val 
changes under leucine deprived, nutrient deprived and control conditions over a 72-
hour period.  
Cellular lysate amino acids levels were analysed using our validated ID-LC-MS/MS method 
Significant changes in all amino acids were noted in response to both leucine and nutrient 
deprivation. A – Glutamic acid concentration was shown to decrease significantly under 
control conditions between 12 and 72 hours (p value = <0.0001). Additionally, a highly 
significant decrease was observed between control and leucine deprived cells and control and 
nutrient deprived cells at 24 hours p value = <0.0001 and 0.0001 respectively. B, D, E and F 
– Significant increases in isoleucine, phenylalanine, tyrosine and valine were seen in leucine 
deprived cells after 12 hours p value = 0.0079 (Ile) and <0.0001 (Phe, Tyr and Val). Analysis 
additionally showed that in nutrient deprivation all amino acids are significantly decreased. C 
– Leucine deprivation was shown to have an immediate impact on the levels of intracellular 
leucine with a significant difference between leucine concentration under leucine deprivation 
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Table 6.3.1 – Pairwise comparison of Glu, Ile, Leu, Phe, Tyr and Val under control and leucine deprived condition at 12-hour and 24-hour time points. 
Amino Acid  C12 C24 LD12 LD24 
Pairwise Comparison 
C12 vs C24 LD12 vs LD24 C24 vs LD24 
Glutamate   130.7 ± 7.402 133.2 ± 10.02 129.0 ± 7.896 49.36 ± 6.102 0.9980 <0.0001 <0.0001 
Amino Acid C12 C24 LD12 LD24 
Pairwise Comparison 
C12 vs C24 LD12 vs LD24 C12 vs LD12 
Isoleucine 23.13 ± 0.752 24.42 ± 2.209 36.51 ± 3.283 25.53 ± 1.905 0.9787 0.0016 0.0018 
Leucine  26.40 ± 0.839 26.64 ± 1.954 1.867 ± 0.013 1.245 ± 0.112 <0.0001 0.9891 <0.0001 
Phenylalanine 16.21 ± 0.674 18.04 ± 1.757 32.24 ± 1.581 19.20 ± 1.582 0.9086 0.0006 0.0004 
Tyrosine  16.68 ± 0.652 18.70 ± 1.828 29.24 ± 1.548 17.81 ± 1.188 0.8695 0.0016 0.0031 
Valine  30.54 ± 0.778 28.83 ± 2.827 48.68 ± 2.295 33.14 ± 2.961 0.9816 0.0101 0.0114 
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Table 6.3.2 – Pairwise comparison Glu, Ile, Leu, Phe, Tyr and Val under control, leucine deprived and nutrient deprived conditions analysed at 12 
hours. 
Amino Acid  C12 LD12 ND12 




C12 vs LD12 C24 vs ND12 LD12 vs ND12 
Glutamate   130.7 ± 7.402 129.0 ± 7.896 132.4 ± 11.75 0.03080 0.9698 0.9933 0.9931 0.9668 
Isoleucine  23.13 ± 0.752 36.51 ± 3.283 4.295 ± 0.468 58.47 <0.0001 0.0079 0.0007 <0.0001 
Leucine  26.40 ± 0.839 1.867 ± 0.013 5.885 ± 0.747 33.1 <0.0001 <0.0001 <0.0001 0.0035 
Phenylalanine  16.21 ± 0.674 32.24 ± 1.581 4.456 ± 1.079 137.9 <0.0001 <0.0001 0.0003 <0.0001 
Tyrosine 16.68 ± 0.652 29.24 ± 1.548 7.037 ± 0.754 115.5  <0.0001 <0.0001 0.0005 <0.0001 
Valine 30.54 ± 0.778 48.68 ± 2.295 5.712 ± 0.685 249.8 <0.0001 <0.0001 <0.0001 <0.0001 
 
C12 – Control 12 Hours, LD12 – Leucine Deprived 12 Hours and ND12 – Nutrient Deprived 12 Hours 
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Table 6.3.3 – Pairwise comparison Glu, Ile, Leu, Phe, Tyr and Val under control, leucine deprived and nutrient deprived conditions analysed at 24 
hours. 
 
Amino Acid  C24 LD24 ND24 




C24 vs LD24 C24 vs ND24 LD24 vs ND24 
Glutamate   133.2 ± 10.02 49.36 ± 6.102 70.30 ± 7.959 31.05 <0.0001 <0.0001 0.0001 0.1817 
Isoleucine  24.42 ± 2.209 25.53 ± 1.905 3.141 ± 0.918 67.66 <0.0001 0.8979 <0.0001 <0.0001 
Leucine  26.64 ± 1.954 1.245 ± 0.112 4.659 ± 1.293 101.0 <0.0001 <0.0001 <0.0001 0.1589 
Phenylalanine  18.04 ± 1.757 19.20 ± 1.582 3.853 ± 5.828 24.96 <0.0001 0.9089 <0.0001 <0.0001 
Tyrosine 18.70 ± 1.828 17.81 ± 1.188 5.815 ± 1.435 23.29  <0.0001 0.9306 <0.0001 <0.0001 
Valine 28.83 ± 2.827 33.14 ± 2.961 3.857 ± 1.415 53.10 <0.0001 0.4502 <0.0001 <0.0001 
 
C24 – Control 24 Hours, LD24 – Leucine Deprived 24 Hours and ND24 – Nutrient Deprived 24 Hours 
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Table 6.3.4 – Pairwise comparison Glu, Ile, Leu, Phe, Tyr and Val under control, leucine deprived and nutrient deprived conditions analysed at 48 
hours. 
Amino Acid  C48 LD48 ND48  




C48 vs LD48 C48 vs ND48 LD48 vs ND48 
Glutamate   84.06 ± 5.161 29.17 ± 2.805 20.22 ± 1.683 94.73 <0.0001 <0.0001 <0.0001 0.2349 
Isoleucine  19.36 ± 2.918 26.84 ± 4.456 0.659 ± 0.211 27.62 <0.0001 0.1836 0.0002 <0.0001 
Leucine  21.53 ± 3.038 1.117 ± 0.218 1.410 ± 0.223 44.03 <0.0001 <0.0001 <0.0001 0.9924 
Phenylalanine  14.25 ± 2.742 16.20 ± 3.025 0.208 ± 0.109 13.68 0.0004 0.8283 0.0021 0.0007 
Tyrosine 13.75 ± 2.326 15.09 ± 2.169 2.348 ± 0.171 14.50 0.0003 0.8643 0.0015 0.0005 
Valine 24.86 ± 5.227  38.12 ± 4.477 0.274 ± 0.271 21.53 0.0001 0.1279 0.0012 0.0002 
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Table 6.3.5 – Pairwise comparison Glu, Ile, Leu, Phe, Tyr and Val under control, leucine deprived and nutrient deprived conditions analysed at 72 
hours. 
Amino Acid  C72 LD72 ND72  




C72 vs LD72 C72 vs ND72 LD72 vs ND72 
Glutamate   43.34 ± 3.513 6.910 ± 0.663 15.89 ± 3.185 39.53 0.0004 0.0003 0.0016 0.1690 
Isoleucine  20.75 ± 2.860 15.55 ± 0.810 0.562 ± 0.101 37.27 0.0004 0.1614 0.0004 0.0020 
Leucine  23.73 ± 1.857 1.265 ± 0.1953 1.272 ± 0.131 144.1 <0.0001 <0.0001 <0.0001 >0.9999 
Phenylalanine  16.04 ± 1.552 10.84 ± 0.847 0.008 ± 0.008 64.18 <0.0001 0.0265 <0.0001 0.0007 
Tyrosine 15.84 ± 1.011 11.03 ± 0.537 2.794 ± 0.158 97.78 <0.0001 0.0054 <0.0001 0.0003 
Valine 29.53 ± 2.175 21.45 ± 2.524 0.090 ± 0.090 62.51 <0.0001 0.0566 <0.0001 0.0006 
 
C72 – Control 72 Hours, LD72 – Leucine Deprived 72 Hours and ND72 – Nutrient Deprived 72 Hours 
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Significant increases in the levels of hBCATc, Beclin 1 and LC3 lipidation were 
reported in leucine deprived cells p value = 0.0460, 0.0259 and 0.0399, 
respectively (Table 6.3.6). Representative Western blots for each proteins and 
bar charts of relative densities are shown in Figure 6.3.2. Analysis of hBCATc, 
LC3I/II, pmTOR and mTOR over a period of 72 hours indicates that under leucine 
deprived conditions levels of hBCATc increase relative to LC3I/II lipidation from 
24 to 72 hours compared to controls, supporting a role for leucine and BCATc in 
regulating autophagy (Figure 6.3.2 and 6.3.3). Moreover, there is a concomitant 
decrease in the level of activated mTOR indicating that protein synthesis is 
decreased supporting a role for BCATc in crosstalk between pathways. 
 
6.3. - Assessment of Mitochondrial Function in Neuronal Model SH-SY5Y 
under Conditions of Leucine Deprivation, Nutrient Deprivation and in 
Response to Leucine Supplementation 
 
The effects of leucine deprivation, nutrient deprivation and leucine 
supplementation on mitochondrial respiration in SH-SY5Y cells was determined 
using an Agilent Seahorse XFe24 Analyser and the application of the Agilent 
Seahorse XF Mito Stress Kit. Differences in baseline respiration and respiration 
following the injection of; complex IV inhibitor oligomycin, mitochondrial uncoupler 
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) and complex I 
and II inhibitors rotenone and antimycin A were assessed by repeated 
measurement one-way analysis of variance with the application of the Geisser-
Greenhouse correction and a post-hoc application of Tukey’s honestly significant 
differences test for each measure. Respiratory graph plots for oxygen 
consumption rate and extracellular acidification rate are shown in Figure 6.3.4 
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and 6.3.5 respectively. Figure 6.3.4 shows that leucine deprivation for 24 hours 
causes perturbations in oxygen consumption rate when compared to control at 24 
hours. Additionally, significant decreases in extracellular oxygen consumption 
rate were observed between control and leucine deprived groups at 24 hours. 
Similar perturbations were observed when cells were deprived of nutrients for 24 
hours with significant differences to control cells at the matched time points. 
Significant differences are also observed between cells deprived of leucine for 48 
hours and 72 hours when compared to nutrient deprived cells at 24 and 72 hours 
and cells supplemented with leucine. 
 
Within treatment groups significant differences in oxygen consumption rate were 
seen for leucine deprivation between 24 hours and 48 hours and between nutrient 
deprived cells at 48 and 72 hours compared to nutrient deprivation for 24 hours. 
Pairwise comparison and mean values of each experimental condition are 
summarised in Table 6.3.7. 
 
Table 6.3.6 – Expression levels of BCATc, Beclin 1 and LC3 in cell maintained under 




(n = 3) 
Leucine Deprived 
(n = 3) 
Unpaired t-test        p 
value 
BCATc  6.910 ± 0.701 40.50 ± 11.73 0.0460 
Beclin 1 1.582 ± 0.158 13.18 ± 3.353 0.0259 
LC3 0.1681 ± 0.035 3.885 ± 1.238 0.0399 
  




Figure 6.3.2 – Western blot analysis of BCATc, Beclin 1 and LC3 in the cellular lysate 
of SH-SY5Y cells maintained under leucine deprived conditions. 
The protein concentration of cellular lysate samples was calculated using the Schaffner and 
Weissmann method (Schaffner W, 1973) and separated on a NuPAGE® Novex® 4-12% Bis-
Tris followed by Western blot analysis using antibodies specific for BCATc, Beclin 1 and LC3 
BCATm (1/1000, 1/1000 and 1/500 dilution respectively). Positive bands were visualised using 
chemiluminescent HRP substrate and an Odyssey® Fc Imaging System (LI-COR 
Biosciences). Integrated area densitometry was carried out using Image Studio Ver 5.2 and 
the results were measured in relation the a-tubulin loading control. A: Sample western blot 
analysis of BCATc and Beclin 1 under control and leucine deprived conditions (n = 3). B: 
Sample western blot analysis of LC3 under control and leucine deprived conditions (n=3). C: 
Bar charts of the relative density of BCATc, Beclin 1 and LC3 under maintained under control 
and leucine deprived conditions. Significant differences were seen in the expression of each 
protein; BCATc p value = 0.0460, Beclin 1 p value = 0.0259 and LC3 p value = 0.0399. *Leu 


































































































Figure 6.3.3 – Western blot analysis of BCATc, LC3I/II, pmTOR and mTOR in the cellular 
lysate of SH-SY5Y cells maintained under leucine deprived conditions over 72 hours. 
The protein concentration of cellular lysate samples was calculated using the Schaffner and 
Weissmann method (Schaffner W, 1973) and separated on a NuPAGE® Novex® 4-12% Bis-
Tris followed by Western blot analysis using antibodies specific for hBCATc, LC3I/II pmTOR 
and mTOR. Positive bands were visualised using chemiluminescent HRP substrate and an 
Odyssey® Fc Imaging System (LI-COR Biosciences). (n =2). 





Figure 6.3.4 – Normalised oxygen consumption rate data from analysis of SH-SY5Y 
cells under normal, leucine deprived, nutrient deprived and leucine supplemented 
conditions.  
Oxygen consumption rate was measured using an Agilent Seahorse XFe24 Analyser with the 
Seahorse XF Cell Mito Stress Test Kit. Cells were mere grown and treated according to the 
methods described in 3.5.21, 3.5.22, 3.5.23 and 3.5.24. Oxygen consumption rate was 
normalised against crystal violet staining of cells post-analysis (3.5.29) (n=3). 
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Figure 6.3.5 – Normalised extracellular acidification rate data from analysis of SH-SY5Y 
cells under normal, leucine deprived, nutrient deprived and leucine supplemented 
conditions.  
Extracellular acidification rate was measured using an Agilent Seahorse XFe24 Analyser with 
the Seahorse XF Cell Mito Stress Test Kit. Cells were mere grown and treated according to 
the methods described in 3.5.21, 3.5.22, 3.5.23 and 3.5.24. extracellular acidification rate was 
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Table 6.3.7 – Pairwise comparison of oxygen consumption rate and extracellular 
acidification rate of SH-SY5Y cells maintained under normal (control), leucine deprived, 
nutrient deprived or leucine supplemented conditions.  
 
Cell Treatments - Pairwise Comparison 
p-values 
OCR ECAR 
Control 24 Hours vs. Control 48 Hours 0.5740 0.2425 
Control 24 Hours vs. Control 72 Hours 0.9958 0.9998 
Control 24 Hours vs. Leucine Deprived 24 Hours 0.0020 0.0004 
Control 24 Hours vs. Leucine Deprived 48 Hours >0.9999 0.4312 
Control 24 Hours vs. Leucine Deprived 72 Hours >0.9999 <0.0001 
Control 24 Hours vs. Nutrient Deprived 24 Hours 0.0360 0.0031 
Control 24 Hours vs. Nutrient Deprived 48 Hours >0.9999 0.0037 
Control 24 Hours vs. Nutrient Deprived 72 Hours 0.7406 0.0137 
Control 24 Hours vs. Supplemented 24 Hours 0.6179 0.0031 
Control 48 Hours vs. Control 72 Hours 0.9997 0.3294 
Control 48 Hours vs. Leucine Deprived 24 Hours 0.0082 0.2425 
Control 48 Hours vs. Leucine Deprived 48 Hours >0.9999 0.0962 
Control 48 Hours vs. Leucine Deprived 72 Hours 0.9983 <0.0001 
Control 48 Hours vs. Nutrient Deprived 24 Hours 0.1514 0.7392 
Control 48 Hours vs. Nutrient Deprived 48 Hours >0.9999 0.0044 
Control 48 Hours vs. Nutrient Deprived 72 Hours 0.9972 0.0128 
Control 48 Hours vs. Supplemented 24 Hours 0.9612 0.0006 
Control 72 Hours vs. Leucine Deprived 24 Hours 0.0020 0.0018 
Control 72 Hours vs. Leucine Deprived 48 Hours >0.9999 0.6623 
Control 72 Hours vs. Leucine Deprived 72 Hours 0.9976 <0.0001 
Control 72 Hours vs. Nutrient Deprived 24 Hours 0.0089 0.0004 
Control 72 Hours vs. Nutrient Deprived 48 Hours >0.9999 0.0038 
Control 72 Hours vs. Nutrient Deprived 72 Hours 0.4915 0.0146 
Control 72 Hours vs. Supplemented 24 Hours 0.3910 0.0146 
Leucine Deprived 24 Hours vs. Leucine Deprived 48 Hours 0.0181 <0.0001 
Leucine Deprived 24 Hours vs. Leucine Deprived 72 Hours 0.0550 <0.0001 
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Cell Treatments - Pairwise Comparison Continued 
p-values 
OCR ECAR 
Leucine Deprived 24 Hours vs. Nutrient Deprived 24 Hours 0.9920 0.9859 
Leucine Deprived 24 Hours vs. Nutrient Deprived 48 Hours 0.3508 <0.0001 
Leucine Deprived 24 Hours vs. Nutrient Deprived 72 Hours 0.1214 <0.0001 
Leucine Deprived 24 Hours vs. Supplemented 24 Hours 0.6404 <0.0001 
Leucine Deprived 48 Hours vs. Leucine Deprived 72 Hours 0.9540 <0.0001 
Leucine Deprived 48 Hours vs. Nutrient Deprived 24 Hours 0.0006 <0.0001 
Leucine Deprived 48 Hours vs. Nutrient Deprived 48 Hours >0.9999 0.0004 
Leucine Deprived 48 Hours vs. Nutrient Deprived 72 Hours 0.0003 0.0031 
Leucine Deprived 48 Hours vs. Supplemented 24 Hours 0.0072 0.2425 
Leucine Deprived 72 Hours vs. Nutrient Deprived 24 Hours 0.0003 <0.0001 
Leucine Deprived 72 Hours vs. Nutrient Deprived 48 Hours 0.9297 <0.0001 
Leucine Deprived 72 Hours vs. Nutrient Deprived 72 Hours 0.0458 <0.0001 
Leucine Deprived 72 Hours vs. Supplemented 24 Hours 0.0011 0.0017 
Nutrient Deprived 24 Hours vs. Nutrient Deprived 48 Hours 0.0116 <0.0001 
Nutrient Deprived 24 Hours vs. Nutrient Deprived 72 Hours 0.0010 <0.0001 
Nutrient Deprived 24 Hours vs. Supplemented 24 Hours 0.0014 <0.0001 
Nutrient Deprived 48 Hours vs. Nutrient Deprived 72 Hours 0.8102 0.9859 
Nutrient Deprived 48 Hours vs. Supplemented 24 Hours 0.1655 0.7140 
Nutrient Deprived 72 Hours vs. Supplemented 24 Hours 0.3400 0.9339 
Leucine Deprived 24 Hours vs. Nutrient Deprived 72 Hours 0.5740 0.2425 
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6.4 Discussion  
 
The multifaceted cellular role of leucine as a nutrient and signalling amino acid 
presents itself as an interesting target with respect to disease pathology. Here, 
the study was focused on the role of leucine as a nitrogen donor in 
neurotransmitter synthesis, leucine regulator of mTOR and its role in autophagy. 
Importantly, for the first time there is evidence that BCAT plays an important 
conduit in regulating the interplay between these two pathways. This data has 
shown that perturbations in the levels of available leucine has significant effects 
on intracellular amino acid levels, activation of the autophagy pathway and cellular 
metabolism. Furthermore, an increase in the expression of hBCATc in line with 
autophagy markers in response to leucine deprived conditions was observed, 
supporting a key role for BCAT in regulating autophagy. 
 
The maintenance of cellular homeostasis relies on effective cellular synthesis and 
degradation, which are often perturbed in disease. Autophagy is the major system 
by which cellular clearance is achieved, with roles in the degradation of whole 
organelles or protein aggregates and removal of cytosolic proteins in a chaperone 
mediated fashion (Cuervo and Wong, 2014, Choi et al., 2013). In instances of 
cellular stress, such as nutrient deprivation, autophagy has a function as a cellular 
survival mechanism acting to prevent cell death (Choi et al., 2013). The function 
of autophagy is especially important in neuronal cells, as damaged organelles 
cannot be redistributed, which if left uncleared can lead to neurotoxicity through 
intracellular build-up (Wong and Cuervo, 2010, Winslow and Rubinsztein, 2008).  
 
The initiation of autophagy is controlled by two protein complexes ULK1 and the 
Beclin1-class III phosphatidylinositol 3-kinase (PI3KC3) with nutrient signalling as 
Fred Hudd | 2020 
 138 
the driving factor. PI3KC3 is essential for the formation of autophagosome 
formation (Rabanal-Ruiz et al., 2017) and the initiation of autophagy through the 
generation of phosphatidylinositol 3-phosphate . Within this mechanism the 
activity of Beclin 1 is mediated by its interaction with binding partners (Xie et al., 
2016), with its pro-autophagic function inhibited through binding with Bcl-2 
(Pattingre et al., 2005). These interactions highlight other possible target for 
Beclin 1, which may play a role in the regulation of autophagy. In this study 
significant increases in hBCATc in response to leucine deprivation together with 
markers of autophagy, Beclin and LC3I/II (Figure 6.3.2 and 6.3.3) were observed. 
This correlated increase could indicate a possible interaction between hBCATc 
and Beclin 1 resulting in activation of the autophagy pathway. The increase in 
these markers indicate that there is an increase in autophagosome synthesis 
rather than increased flux.  
 
The other primary regulator of the initiation of autophagy is mTOR1, which under 
fed conditions suppresses autophagy through the phosphorylation of ULK1 and 
Atg13 and promotes protein synthesis, cellular growth and proliferation by 
phosphorylation of s6 kinase and 4E-BP (Rabanal-Ruiz et al., 2017). In nutrient 
deprivation ULK1 is activated to induce autophagy. Previous studies have 
explored the potential indirect contribution of glutamate dehydrogenase to 
autophagy and its effect on mTOR1 (Meijer and Codogno, 2008). A study reported 
that in combination, glutamine and leucine activate mTOR1 through enhanced α-
ketoglutarate production (Duran et al., 2012). However, the upstream involvement 
of BCAT was not considered. Here, it is shown that activation of mTOR is reduced 
in response to leucine deprivation suggesting that BCATc may be an important 
scaffold protein between these two signalling pathways. Furthermore, there is a 
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relationship with dysregulated autophagy in neurodegenerative disorders 
contributing to the pathogenic accumulation of protein aggregates, in addition 
accelerated lysosome accumulation in AD (Nixon et al., 2005). In AD brain, both 
autophagic vacuoles and dystrophic neurites were found to be significantly 
increased in AD brain. This accelerated accumulation may occur by an increase 
in synthesis or perturbation of the autophagosome pathway resulting in the 
autophagosome-lysosome fusion disruption (Orr and Oddo, 2013). Moreover, 
these studies showed a correlation between the levels of Aβ and γ-secretase and 
these autophagic vacuoles indicating that this imbalanced clearance could 
contribute to elevated Aβ in the brain. This imbalance between autophagosome 
formation and clearance is considered an early event in AD pathogenesis.  
 
Related studies by our group have shown the rapamycin, a positive regulator of 
autophagy and inhibitor of mTOR also increase the level of BCATc. Moreover, in 
this study an increase in the level of Aβ generated (Harris et al., 2020) through 
increased autophagosome synthesis was shown. Interestingly, this increase in 
Aβ was alleviated through incubation with leucine. Together this data shows that 
in addition to leucine and BCAT regulating glutamate it also plays a key role in 
autophagy. As discussed, the levels of BCATc are significantly increased in AD 
brain relative to matched controls (Hull et al., 2015). I propose that this increased 
level of BCAT could contribute to increased autophagosome synthesis. As 
autophagosome clearance is impaired this sustained activity by BCAT will 
promote aggregate accumulation contributing to pathology. 
 
The mechanisms by which hBCAT regulates autophagy could be through its 
redox-active CXXC motif. The hBCAT proteins are unique amongst the 
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aminotransferase proteins with respect to their regulation by changes in the redox 
environment. In response to oxidation (Conway et al., 2004, Conway et al., 2003) 
S-nitrosation (Conway et al., 2008)or S-glutathionylation the hBCAT proteins are 
differentially inactivated dependent on the modification. Our group has 
demonstrated that the reactive thiol is the N-terminal redox sensor and the C-
terminal cysteine is the resolving cysteine, permitting reversible regulation. 
Previous work has also shown that in vitro the BCAT proteins have novel thiol 
oxidoreductase activity that can accelerate the refolding of reduced and 
denatured RNase, in particular when S-glutathionylated (Hull et al., 2015). This 
intriguing regulatory feature of BCAT was also shown to govern their interaction 
with protein disulphide isomerase, a thiol disulphide isomerase, where BCAT was 
shown to increase the rate of refolding by PDI supporting a chaperone role for 
BCAT in protein folding (Hull et al., 2015). Several other metabolic proteins, 
isolated from neuronal IMR32 cells, were also shown to have peroxide-mediated 
redox associations with BCAT (Coles et al., 2009). These proteins have either 
known reactive cysteine residues or proteins with phosphorylation sites that are 
directly involved or controlled by G protein cell signalling, known to be modulated 
by peroxide. Therefore, as indicated in other studies BCAT may have roles as a 
chaperone or for scaffolding in regulating autophagy facilitating crosstalk with the 
mTOR pathway.  Understanding how leucine supplementation reverses or control 
autophagy mediated Aβ generation will be an interesting target for future 
therapies.   
 
In conclusion this work has shown that leucine and nutrient deprivation causes a 
significant decrease in intracellular glutamic acid and causes increased 
expression of markers of autophagy Beclin 1 and LC3. Furthermore, these 
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findings further support previously seen trends by our group and highlight a role 
for BCAT in autophagy. Metabolic analysis has additionally shown that in cases 
of acute leucine deprivation cellular metabolism is significantly altered. Moving 
forward additional research into the role of leucine in disease and the effect of 
leucine deprivation on cellular metabolism could give rise to promising diagnostic 
and therapeutic targets for not only neurodegenerative disease but conditions 
where altered autophagy is present. 
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Chapter 7 – Future Work 
 
7.1 – Expansion of Biomarker Data Set 
The promising findings through the analysis of serum hBCAT, branched chain 
and aromatic amino acids have shown that increased reseaerch in this area could 
yield a viable, novel and differential biomarker for AD and MCI. Through our 
collaboration we have currently collected samples from additional cohorts, which 
include those with subjective cognitive impairment and additional MCI 
participants. These participants have been tested using an alternative cognitive 
assessment, the Rivermead Behavioural Mental Test and have also been ApoE 
genotyped. These additional data sets will allow for the model generated from the 
first study to be tested on larger population and further assess the predictive 
power of these analytes as biomarkers.   
 
7.2 – Evaluating the Effect of hBCAT Knockdown and 
Overexpression Under Leucine Deprived Conditions 
The study of the effect of hBCAT overexpression and knockdown under control 
and leucine deprived conditions would allow for the further exploration of the role 
of hBCAT proteins in BCAA metabolism and their effect on the autophagy 
pathway. Our group has previously used siRNA and mammalian expression 
vectors to knockdown and overexpress hBCAT respectively. The aim would be to 
develop a lentiviral, selectable system to allow for alteration of the protein 
expression and generation of stable cell lines. This system would additionally 
allow for the knockdown of wildtype BCAT and expression of thiol mutated forms 
of the protein.  
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